var title_f22_23_22896="Eosinophilic esophagitis";
var content_f22_23_22896=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eosinophilic esophagitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 14-month-old with failure to thrive and loose stools. Endoscopy demonstrates a thickened furrowed esophagus consistent with eosinophilic esophagitis. These patients commonly have dysphagia with, as well as without, evidence of stricture. Eosinophilic esophagitis is also a common cause of dysphagic in atopic school-aged children. Histology would demonstrate sheets of eosinophils in the lamina propria.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karen Murray, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_23_22896=[""].join("\n");
var outline_f22_23_22896=null;
var title_f22_23_22897="Patient information: Hidradenitis suppurativa (The Basics)";
var content_f22_23_22897=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?19/63/20465\">",
"         Patient information: Boil (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hidradenitis suppurativa (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/hidradenitis-suppurativa-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H258689298\">",
"      <span class=\"h1\">",
"       What is hidradenitis suppurativa?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hidradenitis suppurativa is a condition that causes red, swollen, painful bumps to form on the body, usually in places where the skin rubs together. These bumps can cause so much pain that they make it hard to move. They can smell bad or drain pus or blood. The bumps also tend to linger for weeks or months and keep coming back.",
"     </p>",
"     <p>",
"      People who have hidradenitis suppurativa, also called &ldquo;HS,&rdquo; often have a hard time dealing with their problem. It can make them feel embarrassed and worried. Sometimes the condition can even cause problems in relationships, or in the workplace. If you have this problem, see a doctor or nurse. There are treatments that can help you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H258689313\">",
"      <span class=\"h1\">",
"       What are the symptoms of HS?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptoms are red, swollen, painful bumps. These bumps can drain pus or blood.",
"     </p>",
"     <p>",
"      The bumps usually form in places where the skin rubs together. Common locations include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Armpits",
"       </li>",
"       <li>",
"        On or under the breasts (in women)",
"       </li>",
"       <li>",
"        In the groin area",
"       </li>",
"       <li>",
"        Inner thighs",
"       </li>",
"       <li>",
"        Buttocks",
"       </li>",
"       <li>",
"        Around or near the anus",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The skin problems caused by HS last a long time and get worse over time. Often the skin hardens and scars around the painful bumps. Plus, many bumps can form in a single area and sometimes form tunnels under the skin.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H258689328\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have symptoms of HS, see a doctor or nurse. He or she can look at your skin and find out if HS is the cause of your symptoms. Make sure you tell the doctor or nurse if you feel sad or embarrassed because of your symptoms. The doctor or nurse can help you deal with these problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H258689343\">",
"      <span class=\"h1\">",
"       How is HS treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Antibiotic liquids or gels that you put on the affected areas",
"       </li>",
"       <li>",
"        Antibiotic pills, which you might need to take for a long time",
"       </li>",
"       <li>",
"        Injections of steroid medicines into affected areas to bring down inflammation",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Women with HS sometimes also take hormone treatments to improve their condition. This usually involves taking a birth control pill every day. Sometimes women take other types of hormone medicines, too.",
"     </p>",
"     <p>",
"      People with severe, long-lasting problems can have surgery that helps HS to heal. They can also get special medicines that can reduce inflammation in the skin.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H258689358\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. First, you should know that you did not do anything to cause your condition. It is not your fault. You did not cause it by being unclean. You should also know that you cannot spread your condition to anyone else. It is not &ldquo;contagious.&rdquo;",
"     </p>",
"     <p>",
"      Here are some things you can to reduce your symptoms:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Do not wear tight-fitting clothes.",
"       </li>",
"       <li>",
"        Try to avoid activities that cause your skin to rub against itself a lot.",
"       </li>",
"       <li>",
"        Shower every day and wash areas of HS gently with your fingers. Do not scrub affected areas with a washcloth, loofah, or brush.",
"       </li>",
"       <li>",
"        Stop smoking, if you smoke. People who smoke are more likely to have HS.",
"       </li>",
"       <li>",
"        Lose weight, if you are overweight. HS is more common and more severe in people who are overweight.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H258689373\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/63/20465?source=see_link\">",
"       Patient information: Boil (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?22/23/22897?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83523 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6D34BE7A96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_23_22897=[""].join("\n");
var outline_f22_23_22897=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H258689298\">",
"      What is hidradenitis suppurativa?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H258689313\">",
"      What are the symptoms of HS?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H258689328\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H258689343\">",
"      How is HS treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H258689358\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H258689373\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/63/20465?source=related_link\">",
"      Patient information: Boil (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_23_22898="Hemi-uterus2";
var content_f22_23_22898=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Noncommunicating right hemiuterus has been removed laparoscopically; left functional unicornuate system is intact",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_23_22898=[""].join("\n");
var outline_f22_23_22898=null;
var title_f22_23_22899="Endotracheal tube adapter";
var content_f22_23_22899=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Bag-valve-mask to transtracheal catheter connector",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 544px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The transtracheal catheter may be connected to a self-inflating bag-valve ventilation device by cutting standard intravenous tubing as pictured. The luer lock end is then connected to the catheter and the cut end is attached to an adapter that has been removed from a 2.5 mm internal diameter endotracheal tube.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_23_22899=[""].join("\n");
var outline_f22_23_22899=null;
var title_f22_23_22900="PUNLMP";
var content_f22_23_22900=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F71290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F71290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Papillary urothelial neoplasm of low malignant potential (PUNLMP)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 200px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    At low power (A, 20x), the discrete and slender papillae of PUNLMP are lined by a thickened multilayered urothelium with absent cytologic atypia. At high power (B, 40x), the cell density is increased compared to normal urothelium. The cell polarity and the umbrella cell layer are preserved.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cristina Magi-Galluzzi, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_23_22900=[""].join("\n");
var outline_f22_23_22900=null;
var title_f22_23_22901="Erythromycin (systemic): Patient drug information";
var content_f22_23_22901=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Erythromycin (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/6/25705?source=see_link\">",
"     see \"Erythromycin (systemic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/32/22025?source=see_link\">",
"     see \"Erythromycin (systemic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8086256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      E.E.S.&reg;;",
"     </li>",
"     <li>",
"      Ery-Tab&reg;;",
"     </li>",
"     <li>",
"      EryPed&reg;;",
"     </li>",
"     <li>",
"      Erythro-RX;",
"     </li>",
"     <li>",
"      Erythrocin&reg;;",
"     </li>",
"     <li>",
"      Erythrocin&reg; Lactobionate-I.V.;",
"     </li>",
"     <li>",
"      PCE&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8086257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Erythro Base&reg;;",
"     </li>",
"     <li>",
"      Apo-Erythro E-C&reg;;",
"     </li>",
"     <li>",
"      Apo-Erythro-ES&reg;;",
"     </li>",
"     <li>",
"      Apo-Erythro-S&reg;;",
"     </li>",
"     <li>",
"      EES&reg;;",
"     </li>",
"     <li>",
"      Erybid&trade;;",
"     </li>",
"     <li>",
"      Eryc&reg;;",
"     </li>",
"     <li>",
"      Novo-Rythro Estolate;",
"     </li>",
"     <li>",
"      Novo-Rythro Ethylsuccinate;",
"     </li>",
"     <li>",
"      Nu-Erythromycin-S;",
"     </li>",
"     <li>",
"      PCE&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10031056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10031058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10031057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702046",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to erythromycin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10031062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10031063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10031065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10031060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694604",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chewable tablet: Chew or crush well. Mix crushed tablet with food. Do not swallow it whole.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10031061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10031066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705565",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablets and capsules:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705408",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Granules:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699473",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) in a refrigerator. Do not freeze. Throw away any part not used after 10 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705506",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Powder:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3761491",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid at room temperature. Throw away any part not used after 35 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10031067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11672 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-D91D1357DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_23_22901=[""].join("\n");
var outline_f22_23_22901=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086256\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086257\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031056\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031058\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031057\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031062\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031063\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031065\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031060\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031061\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031066\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031067\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26419?source=related_link\">",
"      Erythromycin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/61/4052?source=related_link\">",
"      Erythromycin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/41/42642?source=related_link\">",
"      Erythromycin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/6/25705?source=related_link\">",
"      Erythromycin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/32/22025?source=related_link\">",
"      Erythromycin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/28/31171?source=related_link\">",
"      Erythromycin (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/47/756?source=related_link\">",
"      Erythromycin (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/6/30818?source=related_link\">",
"      Erythromycin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_23_22902="Etidronate: Drug information";
var content_f22_23_22902=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Etidronate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?43/37/44628?source=see_link\">",
"    see \"Etidronate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26293?source=see_link\">",
"    see \"Etidronate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F13132424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Review of Long-term Bisphosphonate Efficacy for Osteoporosis",
"     </span>",
"     <span class=\"collapsible-date\">",
"      May 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       In response to serious postmarketing adverse reactions, including atypical femur fractures, osteonecrosis of the jaw, and esophageal cancer, and a paucity of long-term efficacy data, the FDA conducted a systematic review of long-term bisphosphonate therapy for osteoporosis. To date, randomized controlled trials have shown that bisphosphonate therapy is effective in preventing fractures in trials of 3- to 4-years duration. Therefore, to examine long-term efficacy, three long-term extension trials (involving postmenopausal women) ranging in a duration of treatment from 6-10 years were used in the FDA&rsquo;s analysis. Based on the available long-term clinical trial data, the FDA was unable to identify subgroups of patients who are more likely to benefit from therapy beyond 3-5 years. Continuation of treatment should be based on individual assessment of risks, benefits, and preferences of patients and their physicians.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Until further data are available, the data suggests patients at low risk for fracture (eg, younger patients without a fracture history and bone mineral density [BMD] approaching normal) may be good candidates for discontinuation of therapy after 3-5 years. Patients at increased risk, such as older patients with a history of fracture and a BMD in the osteoporotic range, may benefit from continued therapy.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further investigation into the risks and benefits of long-term therapy, the usefulness of markers of bone turnover or BMD in determining duration or interruption of therapy, and surveillance or fracture risk after therapy discontinuation are needed.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For additional information, please refer to file://www.nejm.org/doi/pdf/10.1056/NEJMp1202619.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F168977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Didronel&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F168978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Co-Etidronate;",
"     </li>",
"     <li>",
"      Mylan-Etidronate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F169015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Bisphosphonate Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F168980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients should receive supplemental calcium and vitamin D if dietary intake is inadequate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Paget's disease:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Initial:",
"     </i>",
"     5-10 mg/kg/day (not to exceed 6 months) or 11-20 mg/kg/day (not to exceed 3 months). The recommended initial dose is 5 mg/kg/day (not to exceed 6 months). Higher doses should be used only when lower doses are ineffective or there is a need to suppress rapid bone turnover (ie, potential for irreversible neurologic damage) or reduce elevated cardiac output. Doses &gt;20 mg/kg/day are",
"     <b>",
"      not",
"     </b>",
"     recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Retreatment:",
"     </i>",
"     Initiate only after etidronate-free period &ge;90 days. Monitor patients every 3-6 months. Retreatment regimens are the same as for initial treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Heterotopic ossification:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Caused by spinal cord injury:",
"     </i>",
"     20 mg/kg/day for 2 weeks, then 10 mg/kg/day for 10 weeks; total treatment period: 12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Complicating total hip replacement:",
"     </i>",
"     20 mg/kg/day for 1 month preoperatively then 20 mg/kg/day for 3 months postoperatively; total treatment period is 4 months",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F168981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F168982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution; specific guidelines are not available, however consider dose reduction.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15881401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F168955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as disodium: 200 mg, 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Didronel&reg;: 400 mg [DSC] [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F168939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F168958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer tablet on an empty stomach with a full glass of plain water (6-8 oz) 2 hours before food. Patients should be instructed to stay upright (not to lie down) after taking the medication.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F168957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic treatment of Paget's disease; prevention and treatment of heterotopic ossification due to spinal cord injury or after total hip replacement",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F169020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Etidronate may be confused with etomidate",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F169013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Bone pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Agranulocytosis, alopecia, amnesia, angioedema, arthralgia, arthritis, asthma  exacerbation, bone fracture, confusion, depression, esophageal cancer, esophagitis, follicular eruption, gastritis, glossitis, hallucination, headache, hypersensitivity reactions, leg cramps, leukopenia, macular rash, maculopapular rash, musculoskeletal pain (sometimes severe and/or incapacitating), osteomalacia, pancytopenia, paresthesia, peptic ulcer disease exacerbation, pruritus, Stevens-Johnson syndrome, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F168961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bisphosphonates or any component of the formulation; overt osteomalacia; patients with abnormalities of the esophagus which delay esophageal emptying, such as stricture or achalasia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F168943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone/joint/muscle pain: Infrequently, severe (and occasionally debilitating) bone, joint, and/or muscle pain have been reported during bisphosphonate treatment. The onset of pain ranged from a single day to several months. Consider discontinuing therapy in patients who experience severe symptoms; symptoms usually resolve upon discontinuation. Some patients experienced recurrence when rechallenged with same drug or another bisphosphonate; avoid use in patients with a history of these symptoms in association with bisphosphonate therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fracture risk: Do not exceed recommended dose or use continuously for &gt;6 months in patients with Paget's disease; risk of osteomalacia or fractures may be increased. Long bones with predominantly lytic lesions may be prone to fracture, particularly in patients unresponsive to treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal mucosa irritation: May cause irritation to upper gastrointestinal mucosa. Esophagitis, dysphagia, esophageal ulcers, esophageal erosions, and esophageal stricture (rare) have been reported with oral bisphosphonates; risk increases in patients unable to comply with dosing instructions. Use with caution in patients with dysphagia, esophageal disease, gastritis, duodenitis, or ulcers (may worsen underlying condition). Discontinue use if new or worsening symptoms develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteonecrosis of the jaw (ONJ): ONJ has been reported in patients receiving bisphosphonates. Risk factors include invasive dental procedures (eg, tooth extraction, dental implants, boney surgery); a diagnosis of cancer, with concomitant chemotherapy or corticosteroids; poor oral hygiene, ill-fitting dentures; and comorbid disorders (anemia, coagulopathy, infection, pre-existing dental disease). Most reported cases occurred after I.V. bisphosphonate therapy; however, cases have been reported following oral therapy. A dental exam and preventative dentistry should be performed prior to placing patients with risk factors on chronic bisphosphonate therapy. The manufacturer's labeling states that discontinuing bisphosphonates in patients requiring invasive dental procedures may reduce the risk of ONJ. However, other experts suggest that there is no evidence that discontinuing therapy reduces the risk of developing ONJ (Assael, 2009). The benefit/risk must be assessed by the treating physician and/or dentist/surgeon prior to any invasive dental procedure. Patients developing ONJ while on bisphosphonates should receive care by an oral surgeon.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Enterocolitis: Use with caution in patients with enterocolitis; diarrhea has been reported at high doses and therapy may need to be withheld.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone mineralization: May retard mineralization of bone; treatment may need delayed or interrupted until callus is present.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Calcium/vitamin D intake: Ensure adequate calcium and vitamin D intake.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F168948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: May enhance the hypocalcemic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of antacids containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Magaldrate; Sodium Bicarbonate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Bisphosphonate Derivatives may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral iron supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Bisphosphonate Derivatives. Specifically, polyvalent cation-containing multivitamins may decrease the absorption of orally-administered bisphosphonate derivatives. Management: Avoid administration of polyvalent cation-containing multivitamins within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Bisphosphonate Derivatives may enhance the hypocalcemic effect of Phosphate Supplements.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May diminish the therapeutic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: Bisphosphonate Derivatives may enhance the adverse/toxic effect of SUNItinib. Specifically, the risk of osteonecrosis of the jaw may be increased.  Management: Monitor for development of osteonecrosis of the jaw in patients receiving sunitinib and bisphosphonates.  Avoid invasive dental procedures if possible.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F168974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Food and/or supplements decrease the absorption and bioavailability of the drug. Management: Administer tablet on an empty stomach with a full glass of plain water or fruit juice (6-8 oz) 2 hours before food. Avoid administering foods/supplements with calcium, iron, or magnesium within 2 hours of drug. Do not take with mineral water or other beverages.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F168950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F168964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been reported in some but not all animal studies. There are no adequate and well-controlled studies in pregnant women. Bisphosphonates are incorporated into the bone matrix and gradually released over time. Theoretically, there may be a risk of fetal harm when pregnancy follows the completion of therapy. Based on limited case reports with pamidronate, serum calcium levels in the newborn may be altered if administered during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F168988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F168965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ensure adequate calcium and vitamin D intake; women and men &gt;50 years of age should consume 1200-1500 mg/day of elemental calcium and 800-1000 units/day of vitamin D. Tablet should be taken with water or fruit juice on an empty stomach; avoid administering foods/supplements with calcium, iron, or magnesium within 2 hours of drug. Do not take with mineral water or with other beverages.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F168963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Etidronate Disodium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (60): $244.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (60): $489.04",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F168953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Paget&rsquo;s disease: Alkaline phosphatase; pain; serum calcium and 25(OH)D",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F168956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcium (total): Adults: 9.0-11.0 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Didronat (TR);",
"     </li>",
"     <li>",
"      Didronate (DK, FI, NO, SE);",
"     </li>",
"     <li>",
"      Didronel (AT, AU, CH, DE, FR, GB, GR, HK, IE, JP, LU, NL, NZ, PT);",
"     </li>",
"     <li>",
"      Difosfen (AR, CO, MY, SG, TH, UY);",
"     </li>",
"     <li>",
"      Dinol (KP);",
"     </li>",
"     <li>",
"      Diphos (DE);",
"     </li>",
"     <li>",
"      Disonate (IN);",
"     </li>",
"     <li>",
"      Etibon (TW);",
"     </li>",
"     <li>",
"      Etidrate (NZ);",
"     </li>",
"     <li>",
"      Etidron (IT);",
"     </li>",
"     <li>",
"      Etidronat Jenapharm (DE);",
"     </li>",
"     <li>",
"      Oestrodidronel (BE);",
"     </li>",
"     <li>",
"      Ostedron (PL);",
"     </li>",
"     <li>",
"      Osteotop (CN, PE);",
"     </li>",
"     <li>",
"      Osteum (ES);",
"     </li>",
"     <li>",
"      Yilin (CL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F168942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases bone resorption by inhibiting osteocystic osteolysis; decreases mineral release and matrix or collagen breakdown in bone",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F168960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 1-3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Can persist for 12 months without continuous therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: ~3%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: None",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 1-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine (as unchanged drug); feces (as unabsorbed drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Dental Association Council on Scientific Affairs, &ldquo;Dental Management of Patients Receiving Oral Bisphosphonate Therapy: Expert Panel Recommendations,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 2006, 137(8):1144-50. Available at file://jada.ada.org/cgi/content/full/137/8/1144",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/23/22902/abstract-text/16873332/pubmed\" id=\"16873332\" target=\"_blank\">",
"        16873332",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Assael LA, &ldquo;Oral Bisphosphonates as a Cause of Bisphosphonate-Related Osteonecrosis of the Jaws: Clinical Findings, Assessment of Risks, and Preventive Strategies,&rdquo;",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 2009, 67(5 Suppl):35-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/23/22902/abstract-text/19371813/pubmed\" id=\"19371813\" target=\"_blank\">",
"        19371813",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Author Unknown, \"Safety Update: Bone-Building Drugs: Risks Explained,\"",
"      <i>",
"       Consum Rep Health",
"      </i>",
"      , 2006, 18(5):3.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Edwards BJ, Hellstein JW, Jacobsen PL, et al, \"Updated Recommendations for Managing the Care of Patients Receiving Oral Bisphosphonate Therapy: An Advisory Statement From the American Dental Association Council on Scientific Affairs,\"",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 2008, 139(12):1674-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/23/22902/abstract-text/19047674/pubmed\" id=\"19047674\" target=\"_blank\">",
"        19047674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Filleul O, Crompot E, and Saussez S, \"Bisphosphonate-Induced Osteonecrosis of the Jaw: A Review of 2,400 Patient Cases,\"",
"      <i>",
"       J Cancer Res Clin Oncol",
"      </i>",
"      , 2010, 136(8):1117-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/23/22902/abstract-text/20508948/pubmed\" id=\"20508948\" target=\"_blank\">",
"        20508948",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      French AE, Kaplan N, Lishner M, et al, &ldquo;Taking Bisphosphonates During Pregnancy,&rdquo;",
"      <i>",
"       Can Fam Physician",
"      </i>",
"      , 2003, 49:1281-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/23/22902/abstract-text/14594094/pubmed\" id=\"14594094\" target=\"_blank\">",
"        14594094",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gray RE, &ldquo;Severe Reaction to Diphosphonate,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1988, 297(6655):1042.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lo JC, O'Ryan FS, Gordon NP, et al, &ldquo;Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure,&rdquo;",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 2010, 68(2):243-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/23/22902/abstract-text/19772941/pubmed\" id=\"19772941\" target=\"_blank\">",
"        19772941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marx RE, Sawatari Y, Fortin M, et al, &ldquo;Bisphosphonate-Induced Exposed Bone (Osteonecrosis/Osteopetrosis) of the Jaws: Risk Factors, Recognition, Prevention, and Treatment,&rdquo;",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 2005, 63(11):1567-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/23/22902/abstract-text/16243172/pubmed\" id=\"16243172\" target=\"_blank\">",
"        16243172",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mavrokokki T, Cheng A, Stein B, et al, &ldquo;Nature and Frequency of Bisphosphonate-Associated Osteonecrosis of the Jaws in Australia,&rdquo;",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 2007, 65(3):415-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/23/22902/abstract-text/17307586/pubmed\" id=\"17307586\" target=\"_blank\">",
"        17307586",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ralston SH, &ldquo;Pathogenesis of Paget's Disease of Bone,&rdquo;",
"      <i>",
"       Bone",
"      </i>",
"      , 2008, 43(5):819-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/23/22902/abstract-text/18672105/pubmed\" id=\"18672105\" target=\"_blank\">",
"        18672105",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Storm T, Thamsborg G, Steiniche T, et al, &ldquo;Effect of Intermittent Cyclical Etidronate Therapy on Bone Mass and Fracture Rate in Women With Postmenopausal Osteoporosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1990, 322(18):1265-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/23/22902/abstract-text/2109197/pubmed\" id=\"2109197\" target=\"_blank\">",
"        2109197",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Watts NB, Harris ST, Genant HK, et al, &ldquo;Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1990, 323(2):73-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/23/22902/abstract-text/2113611/pubmed\" id=\"2113611\" target=\"_blank\">",
"        2113611",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Whyte MP, &ldquo;Clinical Practice. Paget's Disease of Bone,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 355(6):593-600.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/23/22902/abstract-text/16899779/pubmed\" id=\"16899779\" target=\"_blank\">",
"        16899779",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wysowski DK, &ldquo;Reports of Esophageal Cancer With Oral Bisphosphonate Use,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(1):89-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/23/22902/abstract-text/19118315/pubmed\" id=\"19118315\" target=\"_blank\">",
"        19118315",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8426 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-2B8F6805EC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_23_22902=[""].join("\n");
var outline_f22_23_22902=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13132424\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168977\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168978\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169015\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168980\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168981\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168982\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881401\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168955\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168939\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168958\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168957\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169020\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169013\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168961\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168943\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299302\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168948\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168974\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168950\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168964\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168988\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168965\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168963\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168953\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168956\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038614\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168942\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168960\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8426\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8426|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/37/44628?source=related_link\">",
"      Etidronate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26293?source=related_link\">",
"      Etidronate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_23_22903="Ocular manifestations of rheumatoid arthritis";
var content_f22_23_22903=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ocular manifestations of rheumatoid arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/23/22903/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/23/22903/contributors\">",
"     Reza Dana, MD, MPH, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/23/22903/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/23/22903/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/23/22903/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/23/22903/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/23/22903/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/23/22903/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid arthritis (RA) is a common and chronic systemic inflammatory disease of unknown etiology that primarily involves joints. Extraarticular manifestations are also observed, including ophthalmic involvement. The clinical course of the ocular disease may be quite variable.",
"   </p>",
"   <p>",
"    The importance of the early diagnosis of ophthalmic disease in the patient with RA cannot be overemphasized since it permits the timely management of potentially serious sight-threatening complications. The presence of ocular disease may also be an indication of ongoing systemic disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, ocular involvement, in particular severe dry eye, may exist independently from severe articular disease and should be evaluated in all patients with RA regardless of extra-ophthalmic manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues relating to the ocular manifestations of RA are discussed in this review. The anatomy of the relevant structures is depicted in the figure (",
"    <a class=\"graphic graphic_figure graphicRef62615 \" href=\"UTD.htm?8/23/8561\">",
"     figure 1",
"    </a>",
"    ). The articular and other nonarticular clinical manifestations of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link\">",
"     \"Clinical features of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=see_link\">",
"     \"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CORNEAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corneal involvement in patients with RA is a significant complication in those with Sj&ouml;gren's and sicca syndromes. Corneal inflammation unrelated to dry eye and involving corneal melting may infrequently occur also.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Sj&ouml;gren's and sicca syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although no consensus definition of Sj&ouml;gren's syndrome (SS) exists, the classic triad of this syndrome consists of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mucosal dryness. Dry eyes and dry mouth are termed keratoconjunctivitis sicca (KCS) and xerostomia, respectively.",
"     </li>",
"     <li>",
"      Positive (minor salivary gland) biopsy",
"     </li>",
"     <li>",
"      Serologic evidence of autoantibodies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sj&ouml;gren's syndrome may be either primary or secondary, with RA being the most common underlying condition in secondary disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link\">",
"     \"Classification and diagnosis of Sj&ouml;gren's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    KCS, as a manifestation of lacrimal gland pathology, is the most common ophthalmic manifestation of RA, occurring in as many as 15 to 25 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/4\">",
"     4",
"    </a>",
"    ]. Symptomatic and objective signs of KCS are central to the diagnosis of SS, and, whenever in doubt, an ophthalmologist should be consulted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Clinical features of ocular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SS often complain of dryness, foreign body sensation, burning, or photophobia. Since ocular surface lubrication is maintained by a balance between fluid secretion and loss (largely by evaporation), patients with KCS have an aggravation of symptoms with exposure to dry or windy environments (which increase evaporative loss of the tear film).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Slit lamp examination of patients with KCS reveals conjunctival injection, decreased tear meniscus, and devitalized surface epithelial cells that stain with Rose Bengal or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    dyes (",
"    <a class=\"graphic graphic_picture graphicRef59477 \" href=\"UTD.htm?17/17/17695\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef75373 \" href=\"UTD.htm?32/59/33726\">",
"     picture 2",
"    </a>",
"    ). Filamentary keratitis, a condition in which epithelial debris and strands with adherent mucus attach to the corneal surface, is a particularly painful and bothersome consequence of KCS (",
"    <a class=\"graphic graphic_picture graphicRef52614 \" href=\"UTD.htm?34/56/35713\">",
"     picture 3",
"    </a>",
"    ). A Schirmer's test may be of diagnostic value but is notoriously unreliable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link\">",
"     \"Classification and diagnosis of Sj&ouml;gren's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Treatment recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic options for KCS of any cause always include the use of artificial tear substitutes. We strongly prefer nonpreserved preparations since they can be used frequently with no adverse effect from the usual preservatives found in topical preparations. Patients with significant mucus overproduction or filamentary keratitis are best treated with topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    (10 percent) as a mucolytic agent (this can be specially prepared for ophthalmic use in most well-equipped pharmacies). Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    -A, when used twice daily for a prolonged period (greater than three to four months), may significantly decrease dry eye symptoms, decrease ocular surface inflammation, and, in some cases, enhance lacrimation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with severe KCS, punctal occlusion is the treatment of choice, since it is a highly effective method for maximizing the preservation of tears. This technique involves sealing of the lacrimal puncta, which are the openings to the nasolacrimal ducts that drain the tears. Our usual approach is to begin with preliminary temporary occlusion, using collagen or silicone plugs (",
"    <a class=\"graphic graphic_picture graphicRef61760 \" href=\"UTD.htm?29/53/30544\">",
"     picture 4",
"    </a>",
"    ) to ensure that punctal occlusion does not result in excess tear accumulation (epiphora) and to avoid a permanent change in the small minority of patients who might regain near-normal lacrimal function with appropriate therapy. When indicated, laser or hand-held thermal cautery energy can be used for a more permanent closure. It is important to realize that punctal occlusion is a tear preservation strategy; as a result, it is of little benefit, unless supplemented with artificial lubricants, in those with minimal to no tear production.",
"   </p>",
"   <p>",
"    The use of slow-release artificial inserts may provide continuous lubrication without surgical intervention; these inserts also require some wetting of the ocular surface prior to becoming clinically beneficial.",
"   </p>",
"   <p>",
"    Oral muscarinic agents, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/36/33344?source=see_link\">",
"     pilocarpine",
"    </a>",
"    , have become increasingly popular in the treatment of exocrine dysfunction in this disorder. While both oral pilocarpine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12932?source=see_link\">",
"     cevimeline",
"    </a>",
"    have been approved for use in dry mouth in Sj&ouml;gren&rsquo;s syndrome, only pilocarpine has been approved for use in dry eye. Common side effects of pilocarpine include those from cholinergic stimulation, including gastrointestinal disturbance and sweating. Initially, we usually begin pilocarpine at a dose of 5 mg twice daily, which is gradually increased over several weeks to 20 to 25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in divided doses, if adequately tolerated. While patients may get significant relief from xerostomia, efficacy with KCS is more variable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/12/26826?source=see_link\">",
"     \"Treatment of dry eyes in Sj&ouml;gren's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some patients, these conservative measures are inadequate to control the KCS, which can be complicated by nonhealing epithelial defects (",
"    <a class=\"graphic graphic_picture graphicRef50444 \" href=\"UTD.htm?33/13/34015\">",
"     picture 5",
"    </a>",
"    ). Among those with such defects, expert management by a cornea and external disease specialist is mandatory. Treatment usually consists of the judicious use of a bandage contact lens and, if necessary, a tarsorrhaphy (lid closure procedure). Not infrequently, particularly in cases of secondary Sj&ouml;gren's syndrome, severe KCS is associated with corneal melting; in this setting, systemic immunosuppression may be required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Corneal inflammation and melting",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to KCS, corneal involvement in RA may involve significant inflammation, frequently in association with anterior scleritis but sometimes without scleritis. One study, for example, found that 43 percent of patients with scleritis had associated corneal involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/1\">",
"     1",
"    </a>",
"    ]. A corneal &ldquo;melt&rdquo; refers to the clinical characterization of collagen breakdown initiated by significant inflammation in the corneal extracellular matrix.",
"   </p>",
"   <p>",
"    The severity of the corneal inflammation often parallels the severity of the scleritis but can occur in eyes with little scleral inflammation. However, these entities probably represent different manifestations of similar pathologic processes whose common denominator is collagenolysis. This process may be due in part to the upregulation of proinflammatory cytokines; these molecules subsequently trigger corneal cells to produce a number of proteolytic enzymes that can effectively degrade the extracellular matrix [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are a number of descriptive terms that depict various stages and extent of corneal inflammation in RA. These include stromal keratitis, sclerosing keratitis, keratolysis, marginal furrowing or guttering, and peripheral ulcerative keratitis (PUK) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common form of corneal melt in RA is PUK. This disorder is not exclusive to RA and may be observed in those with a variety of other systemic immune-mediated conditions, including the vasculitides (eg, granulomatosis with polyangiitis [Wegener&rsquo;s]). In PUK, adjacent conjunctival and episcleral tissues reveal an abundance of lymphocytes and macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/9\">",
"     9",
"    </a>",
"    ]. These cells, particularly macrophages, may release significant quantities of proinflammatory cytokines and proteases that can exacerbate the stromal breakdown.",
"   </p>",
"   <p>",
"    Removal of these inciting inflammatory cells may explain the beneficial effect of conjunctival resection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/10\">",
"     10",
"    </a>",
"    ]. Ongoing rheumatoid keratitis, as well as corneal scarring from antecedent corneal disease, may require transplantation; however, the visual and survival prognoses of these grafts tend to be relatively poor [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Corneal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corneas compromised by an inadequate tear film are also susceptible to infection. Patients with poor corneal surface, as occurs in RA, are at increased risk of corneal infection. Cases of corneal melting that are progressive and difficult to control should, therefore, be cultured (and recultured if necessary) to exclude microbial disease. Most cases of bacterial corneal ulcers in patients with RA and SS are associated with Gram positive organisms, particularly Staphylococcus and Streptococcus species [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EPISCLERITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Episcleritis may be a manifestation of RA, occurring in less than 1 percent of ambulatory patients in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/1\">",
"     1",
"    </a>",
"    ]. On the other hand, nearly 6 percent of those presenting to an ophthalmology clinic had RA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Episcleritis is typically acute in onset, with patients describing discomfort rather than pain (",
"    <a class=\"graphic graphic_picture graphicRef82109 \" href=\"UTD.htm?13/18/13602\">",
"     picture 6",
"    </a>",
"    ). The disorder is usually benign and self-limiting and is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/80?source=see_link\">",
"     \"Episcleritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SCLERITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with episcleritis, scleritis is associated with a more ominous prognosis with respect to ocular morbidity and associated extraarticular manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/2,3,13\">",
"     2,3,13",
"    </a>",
"    ]. The reported incidence of scleritis in patients with RA has ranged from 0.7 to 6.3 percent, although as many as 33 percent of all patients presenting to an ophthalmologist with scleritis may have associated RA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to scleritis are discussed in detail separately. The following discussion reviews those features of scleritis specific to RA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/32/22023?source=see_link\">",
"     \"Clinical manifestations and diagnosis of scleritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/15/11511?source=see_link\">",
"     \"Treatment of scleritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with scleritis associated with RA are older and tend to have bilateral disease more often than those with scleritis due to non-rheumatoid conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/3\">",
"     3",
"    </a>",
"    ]. Diffuse anterior scleritis is the most common and least severe form of scleritis (with or without RA) and usually responds well to systemic immunosuppressive therapy (",
"    <a class=\"graphic graphic_picture graphicRef57004 \" href=\"UTD.htm?16/18/16687\">",
"     picture 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Necrotizing scleritis without inflammation (scleromalacia perforans) is characterized by severe thinning of the sclera in an otherwise clinically uninflamed and painless &ldquo;white&rdquo; eye. Since such patients do not typically complain of ocular discomfort, it is essential for clinicians taking care of patients with long-standing RA to examine behind the eyelids to fully examine the eyes to identify the asymptomatic thinning of the sclera that often appears bluish (from the subjacent choroid) (",
"    <a class=\"graphic graphic_picture graphicRef51568 \" href=\"UTD.htm?27/18/27937\">",
"     picture 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients with RA and scleritis may have more advanced joint disease and extraarticular manifestations than those without scleritis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Scleritis (particularly the inflammatory necrotizing subtype) in the patient with RA may also reflect underlying systemic vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/1,2,13\">",
"     1,2,13",
"    </a>",
"    ]. Because of the general increase in disease activity, RA patients with scleritis appear to have a higher mortality in the absence of immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Treatment recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although topical medications may provide symptomatic relief, systemic therapy is required to treat and reverse the course of scleritis or corneal ulcerative disease in patients with RA. The therapy needs to be individualized according to the severity of the patient's condition and comorbidities, response to therapy, and side effects.",
"   </p>",
"   <p>",
"    Therapeutic failure is defined as persistent inflammation after two to three weeks of therapy or progression of the scleritis to a more severe variant. In non-necrotizing disease, such as diffuse or nodular scleritis, induction of remission is usually first attempted with systemic glucocorticoids and nonsteroidal antiinflammatory drugs (NSAIDs), depending upon the severity of the scleritis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In mild cases, we usually begin with an NSAID alone. We have the most experience with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      (slow release formulation at 75 mg BID),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/41/25240?source=see_link\">",
"       diflunisal",
"      </a>",
"      (250 to 500 mg BID), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      (375 to 500 mg BID).",
"     </li>",
"     <li>",
"      In moderately severe disease (eg, severe diffuse or nodular scleritis), we usually begin with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      at 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day. The response to therapy is monitored closely and altered as necessary.",
"     </li>",
"     <li>",
"      In necrotizing disease or disease unresponsive to the above measures, we add",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (10 to 20",
"      <span class=\"nowrap\">",
"       mg/week)",
"      </span>",
"      to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      . An alternative regimen consists of supplementing prednisone with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (1 to 2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day). Remission is usually achieved in the first three weeks, after which the prednisone is tapered.",
"      <br/>",
"      <br/>",
"      In addition to methotrexate and cyclophosphamide, we have the most experience with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (2 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day). Often, multiple agents need to be added (eg, azathioprine or cyclosporine to prednisone) or one drug may have to be substituted for another (eg, methotrexate to cyclophosphamide) to achieve an adequate response and to maintain disease quiescence [",
"      <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/2,3,15\">",
"       2,3,15",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Agents that suppress tumor necrosis factor-alpha (TNF) are useful in treating RA, but there is, as yet, no consensus among ophthalmologists about the usefulness for RA-related ocular indications. The use of anti-TNF therapies for ocular indications remains an empirical one. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link\">",
"       \"Overview of biologic agents in the rheumatic diseases\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Due to the myriad complications that may ensue from systemic immune suppression, as well as from the underlying disease, we strongly recommend that treatment be a joint venture between the patient's ophthalmologist and rheumatologist; this arrangement will hopefully ensure that the regimen can be tailored to the patient's response and that iatrogenic complications can be handled expeditiously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical management is usually not necessary in patients with RA and scleritis. However, the late diagnosis of necrotizing disease with severe scleral thinning or impending globe perforation may require urgent surgical management. Surgical tectonic grafts of corneoscleral tissue or fascia lata may be required [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/16\">",
"     16",
"    </a>",
"    ]. As a general rule, surgery should not be performed until appropriate medical management has been instituted, since surgery can incite even more ocular destruction. In patients with large scleral defects or perforations, pulse intravenous glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    may be necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OTHER OCULAR DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior uveitis, in the absence of scleritis, is not significantly more common in RA than in the general population (",
"    <a class=\"graphic graphic_figure graphicRef57690 \" href=\"UTD.htm?41/35/42549\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/17\">",
"     17",
"    </a>",
"    ]. However, anterior or posterior uveitis can be found contiguous to anterior or posterior scleritis, respectively.",
"   </p>",
"   <p>",
"    Several other ocular disorders, particularly those resulting from therapy, may be observed in patients with RA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tissue edema and intraocular inflammation secondary to scleritis may cause glaucoma by altering the anatomy and functional outflow of the eye's aqueous drainage system. Glucocorticoid therapy can also lead to increases in intraocular pressure and to glucocorticoid-induced glaucoma.",
"     </li>",
"     <li>",
"      Ocular inflammation and its treatment by local or systemic glucocorticoids may lead to cataracts. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"       \"Major side effects of systemic glucocorticoids\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Retinal pigment epithelial toxicity may be due to the administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      ; all patients should be monitored for this adverse effect via once to twice yearly dilated fundoscopy, central field screening, and color vision and macular threshold testing. In some patients, electrophysiologic testing is used if other more practical tests are deemed insufficiently sensitive. However, this modality is also imperfect. In one study, for example, the electrooculogram was abnormal in 20 percent of patients with RA not treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"       chloroquine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/9/43161?source=see_link\">",
"       \"Antimalarial drugs in the treatment of rheumatic disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among those administered gold salts, the deposition of gold particles (ocular chrysiasis) in the corneal stroma and the lens capsule of the eye may have a dramatic appearance on biomicroscopy, but it does not affect vision and is not an indication for cessation of therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/19\">",
"       19",
"      </a>",
"      ]. Gold has also been implicated as a cause of the Miller Fisher syndrome, which is characterized by bilateral external ophthalmoplegia, generalized areflexia, and ataxia [",
"      <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       Penicillamine",
"      </a>",
"      therapy in RA has also been implicated in optic neuropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Posterior pole morbidity is rare. Venous stasis retinopathy has been described in one patient as part of a hyperviscosity syndrome secondary to polyclonal gammopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other rare complications include cranial nerve palsies, geniculocortical blindness [",
"      <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/23\">",
"       23",
"      </a>",
"      ], and orbital apex syndrome resulting from orbital rheumatoid nodules [",
"      <a class=\"abstract\" href=\"UTD.htm?22/23/22903/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6150356\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The early diagnosis of ophthalmic disease in patients with RA is of high importance because of the need for timely management of potentially serious and sight-threatening complications. In some patients, it may be an indication of ongoing systemic disease activity although there is not necessarily a direct correlation between the eye and systemic disease. The clinical course of ocular disease in RA is quite variable. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Corneal involvement is common in RA, primarily from Sj&ouml;gren&rsquo;s syndrome (SS), but corneal inflammation unrelated to dry eye, and involving corneal melting, may also infrequently occur. There is some evidence suggesting that patients with poor corneal surface, as occurs in RA, have increased risk of corneal infection, most often with Gram positive organisms, such as Staphylococcus or Streptococcus. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Corneal disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Corneal infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Keratoconjuctivitis sicca (KCS) due to Sj&ouml;gren&rsquo;s syndrome is the most common ophthalmic manifestation of RA, occurring in as many as 15 to 25 percent of patients. Symptomatic and objective signs of KCS are central to the diagnosis of SS, and, whenever in doubt, an ophthalmologist should be consulted. Patients with SS often complain of dryness, foreign body sensation, burning, or photophobia. A number of interventions can be of benefit in SS. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Sj&ouml;gren's and sicca syndromes'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/12/26826?source=see_link\">",
"       \"Treatment of dry eyes in Sj&ouml;gren's syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Corneal disease in RA may involve significant inflammation, either with or without concurrent scleritis. The severity of the inflammation often parallels the severity of the scleritis but can occur in eyes with little scleral involvement. Peripheral ulcerative keratitis (PUK) is the most common form of corneal melt, the clinical characterization of collagen breakdown initiated by significant inflammation in the corneal extracellular matrix in RA, and may also be seen in other systemic immune-mediated conditions. Treatment may require conjunctival resection, and some severely affected patients eventually require corneal transplantation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Corneal inflammation and melting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Episcleritis may be a manifestation of RA, occurring in less than 1 percent of ambulatory patients. It is typically described as discomfort, rather than pain, which is acute in onset and is usually benign and self-limiting. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Episcleritis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/5/80?source=see_link\">",
"       \"Episcleritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Scleritis, occurring in between 0.7 and 6.3 percent of patients, is associated with a more ominous prognosis than episcleritis, with respect to ocular morbidity and associated extraarticular manifestations. Diffuse anterior scleritis is the most common and least severe form of scleritis (with or without RA) and usually responds well to systemic treatment with nonsteroidal antiinflammatory drugs, glucocorticoids, or more potent immunosuppressive therapy. Necrotizing scleritis &ldquo;without inflammation&rdquo; (scleromalacia perforans) is characterized by severe thinning of the sclera in an otherwise clinically uninflamed and painless &ldquo;white&rdquo; eye. Since such patients do not typically complain of ocular discomfort, the examination of patients with long-standing RA involves examining behind the eyelids to examine the eyes fully to identify any asymptomatic thinning of the sclera, which often appears bluish (from the subjacent choroid). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Scleritis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/32/22023?source=see_link\">",
"       \"Clinical manifestations and diagnosis of scleritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Individualized systemic therapy is required to treat and reverse the course of scleritis or corneal ulcerative disease in patients with RA, although topical medications may provide symptomatic relief. Treatment should be a collaborative effort involving the patient's ophthalmologist and rheumatologist. Surgery is usually not necessary, but the late diagnosis of necrotizing disease with severe scleral thinning or impending globe perforation often requires urgent surgical management. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment recommendations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Surgery'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/15/11511?source=see_link\">",
"       \"Treatment of scleritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anterior uveitis, in the absence of scleritis, is not significantly more common in RA than in the general population, but anterior or posterior uveitis can be found contiguous to anterior or posterior scleritis, respectively. Glaucoma can be seen as a consequence of scleritis. Disorders resulting from therapy that may occur in patients with RA include glaucoma or cataracts due to glucocorticoids, as well as retinal toxicity from antimalarials. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Other ocular disorders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22903/abstract/1\">",
"      McGavin DD, Williamson J, Forrester JV, et al. Episcleritis and scleritis. A study of their clinical manifestations and association with rheumatoid arthritis. Br J Ophthalmol 1976; 60:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22903/abstract/2\">",
"      Foster CS, Forstot SL, Wilson LA. Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression. Ophthalmology 1984; 91:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22903/abstract/3\">",
"      Fujita M, Igarashi T, Kurai T, et al. Correlation between dry eye and rheumatoid arthritis activity. Am J Ophthalmol 2005; 140:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22903/abstract/4\">",
"      THOMPSON M, EADIE S. Kerato-conjunctivitis sicca and rheumatoid arthritis. Ann Rheum Dis 1956; 15:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22903/abstract/5\">",
"      Barber LD, Pflugfelder SC, Tauber J, Foulks GN. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology 2005; 112:1790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22903/abstract/6\">",
"      Dayer JM, Graham R, Russell G, Krane SM. Collagenase production by rheumatoid synovial cells: stimulation by a human lymphocyte factor. Science 1977; 195:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22903/abstract/7\">",
"      Riley GP, Harrall RL, Watson PG, et al. Collagenase (MMP-1) and TIMP-1 in destructive corneal disease associated with rheumatoid arthritis. Eye (Lond) 1995; 9 ( Pt 6):703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22903/abstract/8\">",
"      Brown SI, Grayson M. Marginal furrows. A characteristic corneal lesion of rheumatoid arthritis. Arch Ophthalmol 1968; 79:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22903/abstract/9\">",
"      Michels ML, Cobo LM, Caldwell DS, et al. Rheumatoid arthritis and sterile corneal ulceration. Analysis of tissue immune effector cells and ocular epithelial antigens using monoclonal antibodies. Arthritis Rheum 1984; 27:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22903/abstract/10\">",
"      Feder RS, Krachmer JH. Conjunctival resection for the treatment of the rheumatoid corneal ulceration. Ophthalmology 1984; 91:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22903/abstract/11\">",
"      Palay DA, Stulting RD, Waring GO 3rd, Wilson LA. Penetrating keratoplasty in patients with rheumatoid arthritis. Ophthalmology 1992; 99:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22903/abstract/12\">",
"      Ormerod LD, Fong LP, Foster CS. Corneal infection in mucosal scarring disorders and Sj&ouml;gren's syndrome. Am J Ophthalmol 1988; 105:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22903/abstract/13\">",
"      Watson PG, Hayreh SS. Scleritis and episcleritis. Br J Ophthalmol 1976; 60:163.",
"     </a>",
"    </li>",
"    <li>",
"     McCluskey PJ, Wakefield D. Scleritis and episcleritis. In: Ocular Infection and Immunity, Pepose JS, Holland GN, Wilhelmus KR (Eds), Mosby, St. Louis 1996. p.642.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22903/abstract/15\">",
"      Foster CS. Immunosuppressive therapy for external ocular inflammatory disease. Ophthalmology 1980; 87:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22903/abstract/16\">",
"      Sainz de la Maza M, Tauber J, Foster CS. Scleral grafting for necrotizing scleritis. Ophthalmology 1989; 96:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22903/abstract/17\">",
"      Kimura SJ, Hogan MJ, O'Connor GR, Epstein WV. Uveitis and joint diseases. Clinical findings in 191 cases. Arch Ophthalmol 1967; 77:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22903/abstract/18\">",
"      Pinckers A, Broekhuyse RM. The EOG in rheumatoid arthritis. Acta Ophthalmol (Copenh) 1983; 61:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22903/abstract/19\">",
"      McCormick SA, DiBartolomeo AG, Raju VK, Schwab IR. Ocular chrysiasis. Ophthalmology 1985; 92:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22903/abstract/20\">",
"      Roquer J, Herraiz J, Maymo J, et al. Miller-Fisher syndrome (Guillain-Barr&eacute; syndrome with ophthalmoplegia) during treatment with gold salts in a patient with rheumatoid arthritis. Arthritis Rheum 1985; 28:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22903/abstract/21\">",
"      Klingele TG, Burde RM. Optic neuropathy associated with penicillamine therapy in a patient with rheumatoid arthritis. J Clin Neuroophthalmol 1984; 4:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22903/abstract/22\">",
"      Sarnat RL, Jampol LM. Hyperviscosity retinopathy secondary to polyclonal gammopathy in a patient with rheumatoid arthritis. Ophthalmology 1986; 93:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22903/abstract/23\">",
"      Sigal LH. The neurologic presentation of vasculitic and rheumatologic syndromes. A review. Medicine (Baltimore) 1987; 66:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22903/abstract/24\">",
"      Konishi T, Saida T, Nishitani H. Orbital apex syndrome caused by rheumatoid nodules. J Neurol Neurosurg Psychiatry 1986; 49:460.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7521 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-199.231.185.123-BC6E475435-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_23_22903=[""].join("\n");
var outline_f22_23_22903=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6150356\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CORNEAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Sj&ouml;gren's and sicca syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Clinical features of ocular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Treatment recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Corneal inflammation and melting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Corneal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EPISCLERITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SCLERITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Treatment recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OTHER OCULAR DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6150356\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7521\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7521|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/23/8561\" title=\"figure 1\">",
"      Eye anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/35/42549\" title=\"figure 2\">",
"      Eye anatomy in cross section",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7521|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/17/17695\" title=\"picture 1\">",
"      Rose Bengal stain in Sjogrens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/59/33726\" title=\"picture 2\">",
"      Devitalization in KCS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/56/35713\" title=\"picture 3\">",
"      Ocular adherent filaments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/53/30544\" title=\"picture 4\">",
"      Epithelial cornea defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/13/34015\" title=\"picture 5\">",
"      Intense corneal inflammation RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/18/13602\" title=\"picture 6\">",
"      Episcleritis in RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/18/16687\" title=\"picture 7\">",
"      Diffuse scleritis in RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/18/27937\" title=\"picture 8\">",
"      Necrotizing scleritis in RA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/9/43161?source=related_link\">",
"      Antimalarial drugs in the treatment of rheumatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=related_link\">",
"      Classification and diagnosis of Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/32/22023?source=related_link\">",
"      Clinical manifestations and diagnosis of scleritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/5/80?source=related_link\">",
"      Episcleritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=related_link\">",
"      Overview of the systemic and nonarticular manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/12/26826?source=related_link\">",
"      Treatment of dry eyes in Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/15/11511?source=related_link\">",
"      Treatment of scleritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_23_22904="Noninfectious complications of continuous peritoneal dialysis";
var content_f22_23_22904=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Noninfectious complications of continuous peritoneal dialysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/23/22904/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/23/22904/contributors\">",
"     Jean L Holley, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/23/22904/contributors\">",
"     Rebecca J Schmidt, DO, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/23/22904/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/23/22904/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/23/22904/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/23/22904/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/23/22904/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/23/22904/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of the noninfectious complications that occur in patients on continuous peritoneal dialysis (eg, continuous ambulatory peritoneal dialysis [CAPD] and continuous cycler peritoneal dialysis [CCPD]) are due to increased intraabdominal pressure resulting from instillation of dialysate into the peritoneal cavity. These include hernia formation, leaks (including hydrothorax or pleuroperitoneal leaks), local edema, back pain, and gastrointestinal problems, such as gastroesophageal reflux and delayed gastric emptying. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41061?source=see_link\">",
"     \"Abdominal hernias in continuous peritoneal dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7528?source=see_link\">",
"     \"Noninfectious complications of peritoneal dialysis catheters\"",
"    </a>",
"    .) Complications of",
"    <span class=\"nowrap\">",
"     CAPD/CCPD",
"    </span>",
"    not specifically related to intraabdominal pressure include hemoperitoneum, pain on infusion of dialysate, electrolyte imbalances, and ultrafiltration failure.",
"   </p>",
"   <p>",
"    Some of these problems will be reviewed here, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Gastroesophageal reflux and delayed gastric emptying",
"     </li>",
"     <li>",
"      Back and abdominal pain",
"     </li>",
"     <li>",
"      Pleural effusion",
"     </li>",
"     <li>",
"      Hemoperitoneum",
"     </li>",
"     <li>",
"      Hypokalemia",
"     </li>",
"     <li>",
"      Disorders of magnesium",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional noninfectious complications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23337?source=see_link\">",
"     \"Problems with solute clearance and ultrafiltration in continuous peritoneal dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41061?source=see_link\">",
"     \"Abdominal hernias in continuous peritoneal dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7528?source=see_link\">",
"     \"Noninfectious complications of peritoneal dialysis catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GASTROESOPHAGEAL REFLUX DISEASE AND DELAYED GASTRIC EMPTYING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nausea, vomiting, a sensation of fullness, and epigastric discomfort are commonly reported by patients on CAPD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Gastrointestinal complaints, such as nausea and fullness, occur in as many as 20 to 40 percent of CAPD patients while approximately 14 percent report frequent vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a paucity of data exists concerning the relationship between these symptoms and the presence of gastroesophageal reflux disease (GERD) or delayed gastric emptying (gastroparesis). There are many potential causes of such symptoms, including uremia, medication-induced gastroenteritis, gastritis, and peptic ulcer disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16120?source=see_link\">",
"     \"Approach to the adult with nausea and vomiting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, if the patient is well-dialyzed (eg, has an adequate",
"    <span class=\"nowrap\">",
"     Kt/V)",
"    </span>",
"    and specific gastrointestinal causes of the symptoms have been excluded, persistent upper gastrointestinal symptoms should prompt consideration of GERD or gastroparesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1962?source=see_link\">",
"     \"Adequacy of peritoneal dialysis\"",
"    </a>",
"    .) Medical management of both GERD and gastroparesis is similar to that in patients not on dialysis. Successful treatment of these problems is important since, if left untreated, they have a significant adverse effect upon the well-being and nutritional status of PD patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9274?source=see_link\">",
"     \"Pathogenesis and treatment of malnutrition in maintenance dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Gastroesophageal reflux disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general pathophysiology of gastrointestinal reflux is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13928?source=see_link\">",
"     \"Pathophysiology of reflux esophagitis\"",
"    </a>",
"    .) Among peritoneal dialysis patients, there are conflicting data concerning the effects of increased intraabdominal pressure on lower esophageal sphincter pressures",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 11 patients on CAPD, no systematic changes in intragastric or lower esophageal sphincter pressures as determined by esophageal manometric studies were observed in response to infusion of 1.5 to 2.5 liters of dialysate [",
"      <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/3\">",
"       3",
"      </a>",
"      ]. Although eight of these patients had chronic complaints of upper gastrointestinal symptoms, their findings on esophageal manometry were the same as those of the three who were asymptomatic.",
"     </li>",
"     <li>",
"      Another study of 13 CAPD patients (four patients who had chronic nausea and vomiting, and nine who were asymptomatic) also found no difference in supine lower esophageal sphincter pressures between the two groups after 2 liters of infused dialysate [",
"      <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/4\">",
"       4",
"      </a>",
"      ]. However, compared to asymptomatic individuals, symptomatic patients were observed to have a significantly higher number of reflux episodes (89 versus 17), reflux episodes lasting &gt;5 minutes (2.3 versus 0.3), and an increased time in which the gastric pH was &lt;4 (75 versus 11 minutes), as determined by 24-hour esophageal pH monitoring [",
"      <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/4\">",
"       4",
"      </a>",
"      ]. These data suggest that GERD is common in symptomatic CAPD patients if the diagnosis is based upon 24-hour gastric pH monitoring rather than findings with esophageal manometry.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to general measures, the treatment of GERD in",
"    <span class=\"nowrap\">",
"     CAPD/CCPD",
"    </span>",
"    patients may involve minimizing the supine intraperitoneal fluid volume. However, since achieving adequate dialysis in",
"    <span class=\"nowrap\">",
"     CAPD/CCPD",
"    </span>",
"    patients depends in large part on the exchange volume, this strategy may require careful tailoring of the dialysis prescription to attain adequate clearance while simultaneously minimizing symptoms of GERD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1962?source=see_link\">",
"     \"Adequacy of peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Delayed gastric emptying",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal gastrointestinal motor function is a complex series of events that requires coordination of the sympathetic and parasympathetic nervous systems, neurons within the stomach and intestine, and the smooth muscle cells of the gut. Abnormalities of this process may lead to a delay in gastric emptying (gastric stasis), a disorder that occurs commonly in certain diseases, particularly diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14312?source=see_link\">",
"     \"Pathogenesis of delayed gastric emptying\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Delayed gastric emptying is relatively common among CAPD patients, including those without diabetes. In a few small studies, delayed gastric emptying of solids and liquids has been detected in approximately 50 percent of both symptomatic and asymptomatic patients undergoing peritoneal dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Normal gastric emptying results have been noted when the peritoneal cavities are drained, thereby suggesting that a mechanical or neurogenic mechanism triggered by the presence of intraabdominal fluid retards gastric emptying [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/6\">",
"     6",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43209?source=see_link\">",
"     \"Etiology and diagnosis of delayed gastric emptying\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14312?source=see_link\">",
"     \"Pathogenesis of delayed gastric emptying\"",
"    </a>",
"    ). The exact mechanism responsible for this correlation is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of gastroparesis in",
"    <span class=\"nowrap\">",
"     CAPD/CCPD",
"    </span>",
"    patients may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Oral or intraperitoneal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Oral or intraperitoneal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unfortunately, although cisapride successfully treats delayed gastric emptying in CAPD patients, its use in dialysis patients is now restricted per the manufacturer's and Federal Drug Administration's recommendations due to the risk of arrhythmias. As of August 2000, prescriptions for the drug can only be filled directly through the manufacturer after providing documentation of need for the drug and assessment of risk factors for cardiac arrhythmias in the individual patient (including a prolonged QTc on the EKG or use of medications known to alter the drug's metabolism, such as macrolide antibiotics, antifungals, and phenothiazines).",
"   </p>",
"   <p>",
"    Thus, oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    is usually the first line therapy, followed by a trial of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    . If symptoms persist, intraperitoneal therapy may be utilized. Intraperitoneal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    , for example, was successful in one patient with refractory gastroparesis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=see_link\">",
"     \"Treatment of delayed gastric emptying\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     BACK PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased mechanical stress on the lumbar spine is common among patients on CAPD; this is due, in part, to the tendency of patients to assume a more lordotic position because of increased intraabdominal pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/14\">",
"     14",
"    </a>",
"    ]. Some patients may also have poor abdominal muscle tone resulting from previous surgeries or poor physical conditioning. These effects increase the mechanical stress on the lumbar spine, thereby causing back pain or sciatica [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/15\">",
"     15",
"    </a>",
"    ]. Underlying degenerative disk disease, facet joint disease, and osteoporosis may further exacerbate the back pain [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18601?source=see_link\">",
"     \"Approach to the diagnosis and evaluation of low back pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other than general therapeutic measures, the treatment of low back pain in CAPD patients may include decreasing the dialysate fill volume. However, since adequate dialysis",
"    <strong>",
"     must",
"    </strong>",
"    be maintained, changing to CCPD may be beneficial, as larger fill volumes may be tolerated when the patient is supine. In those whose back pain is severe, transfer to hemodialysis may be necessary if adequate clearance on CCPD cannot be achieved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/21/13658?source=see_link\">",
"     \"Treatment of acute low back pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PLEURAL EFFUSION DUE TO PLEUROPERITONEAL LEAK",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of a pleural effusion (hydrothorax) in a patient on continuous peritoneal dialysis may be due to systemic volume overload, heart failure, or a local pleural process. The presence of a pleural effusion without other signs of heart failure or of peripheral edema, particularly if the effusion is only right-sided, should prompt a search for a pleuroperitoneal communication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pleural effusion that results from a pleuroperitoneal leak typically occurs early in the course of therapy and is not related to the volume of instilled dialysate; as a result, congenital communications between the pleura and the peritoneum have been hypothesized to be the source of the leak [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Diaphragmatic hernias, for example, may allow dissection of fluid through defects around the major vessels and the esophagus, or through diaphragmatic foramina [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In addition, the negative intrathoracic pressure combined with an increased intraabdominal pressure caused by dialysate instillation may open small defects in the diaphragm and promote the flow of dialysate into the pleural space. In autopsy studies, discontinuities in the tendinous portions of the hemidiaphragms have been observed, thereby supporting the presence of diaphragmatic defects [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acquired diaphragmatic defects may also permit the development of hydrothorax. This is suggested by the finding that acute pleural effusion has been observed as late as eight years after starting peritoneal dialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported incidence of acute pleural effusion in patients being maintained on peritoneal dialysis varies from 1.6 to 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/16,17,19,20\">",
"     16,17,19,20",
"    </a>",
"    ]. In the largest study reported to date, 50 of 3195 patients (1.6 percent) developed acute hydrothorax after starting peritoneal dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/16\">",
"     16",
"    </a>",
"    ]. Women are affected more commonly than men [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with polycystic kidney disease are predisposed to develop pleuroperitoneal leaks. Because of the significantly reduced abdominal capacity of these patients, a marked increase in hydrostatic pressure occurs after the infusion of dialysate, thereby favoring the flow of dialysate from the peritoneum to the chest [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/17,21\">",
"     17,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Clinical characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Presenting symptoms and signs of pleural effusion include dyspnea and inadequate ultrafiltration ability [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/16\">",
"     16",
"    </a>",
"    ]. However, many patients are asymptomatic (26 percent), with the recognition of fluid in the pleural space occurring only after routine physical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/16\">",
"     16",
"    </a>",
"    ]. The right side is more commonly affected than the left, with unilateral right-sided effusions found in 50 to 90 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/17,19\">",
"     17,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most pleural effusions appear early after the initiation of peritoneal dialysis: 50 percent are found within 30 days of starting PD, while 20 percent occur after one year [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/16\">",
"     16",
"    </a>",
"    ]. Overall, these effusions have been reported to occur one day to eight years after beginning PD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/16,17,19\">",
"     16,17,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a pleural effusion resulting from a pleuroperitoneal leak should be suspected in the dyspneic nonedematous patient and in patients in whom ultrafiltration is consistently inadequate. Establishing that fluid in the pleural space is due to a pleuroperitoneal leak is based upon confirming that the fluid is dialysate and that it is leaking from the peritoneum into the pleura. A detailed discussion of the diagnosis and evaluation of this problem is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41477?source=see_link\">",
"     \"Modalities for the diagnosis of abdominal and thoracic cavity defects in peritoneal dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of acute hydrothorax due to pleuroperitoneal leaks depends upon the acuity and severity of the patient's symptoms, and the need",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    desire to continue with PD as a treatment modality. Acute thoracentesis to remove large pleural effusions is rarely required. In most cases, simply draining the peritoneal cavity and avoiding overnight (supine) dwells is sufficient. If the leak is small and the patient has adequate residual function to permit intermittent dialysis (eg, nocturnal PD), PD can be continued.",
"   </p>",
"   <p>",
"    Peritoneal dialysis may also be continued if the estimated duration of dialysis is short, such as the patient who will soon undergo a living-related transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/17,22\">",
"     17,22",
"    </a>",
"    ]. However, although some pleuroperitoneal leaks spontaneously resolve (often after temporary transfer to hemodialysis), cure rates are, at best, only 40 percent with conservative therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/16,17,19,23\">",
"     16,17,19,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemical pleurodesis may be offered to the patient with recurrent pleural effusion unresponsive to conservative measures who needs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    desires to continue with PD. A paucity of literature exists concerning the effectiveness of such therapy. In one review, pleural effusion resolved after pleurodesis in 67 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/24\">",
"     24",
"    </a>",
"    ]. Agents used have included autologous blood, talc, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/17,25,26\">",
"     17,25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/29/37334?source=see_link\">",
"     \"Management of refractory nonmalignant pleural effusions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although temporary cessation of CAPD remains the first-line treatment, video-assisted thoracoscopic pleurodesis or repair may also be an option for patients who failed conservative management [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/27\">",
"     27",
"    </a>",
"    ]. Surgical correction of an identified diaphragmatic defect can also be performed but requires thoracotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/17,28\">",
"     17,28",
"    </a>",
"    ]; this has led some investigators to suggest that thoracoscopy should precede surgery to ensure that a visible, repairable communication is identified.",
"   </p>",
"   <p>",
"    Despite these various treatment options, most patients with pleuroperitoneal leaks ultimately require permanent transfer to hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/16,17,19,23\">",
"     16,17,19,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     HEMOPERITONEUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;A discussion of hemoperitoneum in patients undergoing PD is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24245?source=see_link\">",
"     \"Bloody peritoneal dialysate (hemoperitoneum)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PAIN ON DIALYSATE INFUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal pain often occurs with peritoneal dialysis-associated peritonitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22617?source=see_link\">",
"     \"Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis\"",
"    </a>",
"    .) This symptom may also occur in the absence of peritonitis, frequently in association with infusion of dialysate into the peritoneal cavity.",
"   </p>",
"   <p>",
"    Many patients experience pain on infusion that diminishes during the dwell period. This discomfort is frequently transient, resolving shortly after PD is initiated [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In some patients, however, abdominal pain during dialysate infusion persists; in extreme situations, it may lead to discontinuation of PD.",
"   </p>",
"   <p>",
"    This complaint is thought to be caused by the acidic pH (pH 5.2 to 5.5) of conventional lactate dialysate. Additional contributing factors may include a poor catheter position (such as abutting against the bowel wall or peritoneal cavity surfaces), the dialysate temperature, and a high glucose concentration of hypertonic dialysis solutions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of infusion pain includes the following measures, to be utilized in descending order [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Neutralization of the solution by injecting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      into the bag prior to infusion (2 to 5",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"     </li>",
"     <li>",
"      Slowing the rate of infusion",
"     </li>",
"     <li>",
"      Injection of local anesthetics into the dialysis solution before infusing (1 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      at 50",
"      <span class=\"nowrap\">",
"       mg/exchange)",
"      </span>",
"     </li>",
"     <li>",
"      Incompletely draining the fluid after a dwell period",
"     </li>",
"     <li>",
"      Catheter replacement",
"     </li>",
"     <li>",
"      Discontinuation of PD",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although injecting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    into the dialysis solution before infusion may be effective in alleviating pain [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/31\">",
"     31",
"    </a>",
"    ], the risk of contamination during the injection with the subsequent development of peritonitis is high [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/30\">",
"     30",
"    </a>",
"    ]. To avoid this risk, dialysis solutions with a higher pH (pH 7 to 7.4) (such as bicarbonate and",
"    <span class=\"nowrap\">",
"     bicarbonate/lactate",
"    </span>",
"    dialysis solutions) have been developed.",
"   </p>",
"   <p>",
"    The effectiveness of such alternative solutions compared with conventional lactate solution has been evaluated in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/30,32\">",
"     30,32",
"    </a>",
"    ]. In a randomized, double-blind, cross-over study where pain was recorded using two quantifiable scales, significant reductions in inflow pain were noted when the bicarbonate (38 mM) or",
"    <span class=\"nowrap\">",
"     bicarbonate/lactate",
"    </span>",
"    (25 mM of",
"    <span class=\"nowrap\">",
"     bicarbonate/15",
"    </span>",
"    mM of lactate) solutions were used, as compared with the conventional lactate (40 mM solution) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/30\">",
"     30",
"    </a>",
"    ]. In this study, the",
"    <span class=\"nowrap\">",
"     bicarbonate/lactate",
"    </span>",
"    solution was the most effective in alleviating infusion pain, thereby suggesting that factors other than the pH are involved in infusion pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ELECTROLYTE ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although any disturbance in electrolyte concentration may occur among peritoneal dialysis patients, abnormalities in serum levels of potassium and magnesium are most commonly observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hypokalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike chronic hemodialysis patients, in whom hyperkalemia is more common than hypokalemia, 10 to 35 percent of patients on continuous peritoneal dialysis require potassium supplements [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. A retrospective study of 45",
"    <span class=\"nowrap\">",
"     CAPD/CCPD",
"    </span>",
"    patients found that approximately 30 percent required oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    supplementation with a mean dose of 22 &plusmn; 13",
"    <span class=\"nowrap\">",
"     mEq/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/33\">",
"     33",
"    </a>",
"    ]. Hypokalemic patients complained of weakness more often than those with normal potassium levels. African-American race was a predictor of the need for potassium supplementation, but",
"    <span class=\"nowrap\">",
"     Kt/V,",
"    </span>",
"    etiology of renal failure, age, peritoneal membrane transport type, and oral protein and caloric intake were not. Cultural dietary preferences were thought to be responsible for these findings. Cellular uptake of potassium, prompted by the intraperitoneal glucose load with subsequent insulin release, and bowel losses may also play a role in the hypokalemia observed in PD patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For stable chronic outpatients, liberalization of dietary potassium restriction and, when needed, oral potassium replacement (usually 20",
"    <span class=\"nowrap\">",
"     meq/day,",
"    </span>",
"    based upon individual patient serum potassium determinations) are usually successful treatments for hypokalemia. However, intraperitoneal potassium may also be administered acutely if critical hypokalemia exists [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/37\">",
"     37",
"    </a>",
"    ]. Although intraperitoneal potassium can correct hypokalemia in stable outpatients on PD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/38\">",
"     38",
"    </a>",
"    ], we recommend that oral potassium supplements be used rather than intraperitoneal potassium, due to the risk of contamination (and subsequently, peritonitis) when intraperitoneal instillation is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Magnesium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypermagnesemia, a common finding in PD patients, is due to positive magnesium balance resulting from renal failure and the relatively high dialysate magnesium concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/29/470?source=see_link\">",
"     \"Regulation of magnesium balance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13220?source=see_link\">",
"     \"Causes and treatment of hypermagnesemia\"",
"    </a>",
"    .) Serum magnesium levels are usually elevated in those dialyzed against solutions containing magnesium concentrations of 0.75",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    (1.8",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The typical serum magnesium level in end-stage renal disease patients is 2.4 to 3.6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.0 to 1.5",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    a value usually not associated with clinical symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13220?source=see_link\">",
"     \"Causes and treatment of hypermagnesemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32914?source=see_link\">",
"     \"Symptoms of hypermagnesemia\"",
"    </a>",
"    .) However, an inverse relationship between concentrations of magnesium and intact parathyroid hormone (PTH) raises the possibility that hypermagnesemia suppresses PTH levels, thereby contributing to adynamic bone disease in PD patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/39\">",
"     39",
"    </a>",
"    ]. As a result, although abnormalities in calcium, vitamin D, and phosphorus metabolism are the primary factors, more attention should be focused upon the role of magnesium in leading to the relative high incidence of adynamic bone disease in peritoneal dialysis patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Current peritoneal dialysis solutions contain magnesium concentrations of 0.75, 0.50, and 0.25",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    (1.8, 1.2, and 0.6",
"    <span class=\"nowrap\">",
"     mg/dL).",
"    </span>",
"    As some patients utilizing the 0.25",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    (0.6",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    magnesium concentration become hypomagnesemic, the 0.50",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    (1.2",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    concentration dialysate may be the better choice [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22904/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given that many PD patients are slightly hypermagnesemic, the use of magnesium-containing antacids as phosphate binders is rarely a useful clinical option.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/10/14501?source=see_link\">",
"       \"Patient information: Peritoneal dialysis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3409435\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Noninfectious complications occurring in patients undergoing either continuous ambulatory peritoneal dialysis (CAPD) or continuous cycler peritoneal dialysis (CCPD) are usually a consequence of increased intraabdominal pressure resulting from instillation of dialysate into the peritoneal cavity. These include gastroesophageal reflux (GE) and delayed gastric emptying, back and abdominal pain, and pleural effusion. Additional common issues observed in PD patients include hemoperitoneum, hypokalemia, and dysmagnesemia. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gastroesophageal reflux and delayed gastric emptying should be considered in well-dialyzed patients complaining of nausea, vomiting, fullness and epigastric discomfort. In addition to general measures, the treatment of GE reflux in",
"      <span class=\"nowrap\">",
"       CAPD/CCPD",
"      </span>",
"      patients may involve minimizing the supine intraperitoneal fluid volume. However, since achieving adequate dialysis in",
"      <span class=\"nowrap\">",
"       CAPD/CCPD",
"      </span>",
"      patients depends in large part on the exchange volume, this strategy may require careful tailoring of the dialysis prescription to avoid inadequate small solute clearance. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Gastroesophageal reflux disease and delayed gastric emptying'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A pleuroperitoneal leak should be considered in PD patients with pleural effusion (especially right-sided effusion) without other signs of heart failure. A number of different measures can be utilized based upon severity and underlying cause. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pleural effusion due to pleuroperitoneal leak'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abdominal pain in a PD patient should prompt consideration of peritonitis, catheter malfunction, or possibly infusion pain from high dextrose or acidic dialysate. Infusion pain may be treated with intraperitoneal infusion of bicarbonate. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Pain on dialysate infusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Unlike hemodialysis patients, hypokalemia is fairly common in PD patients. Liberalization of dietary potassium and, often, oral potassium supplementation may be needed. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Electrolyte abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/1\">",
"      Bj&ouml;rvell H, Hylander B. Functional status and personality in patients on chronic dialysis. J Intern Med 1989; 226:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/2\">",
"      Dong R, Guo ZY. Gastrointestinal symptoms in patients undergoing peritoneal dialysis: multivariate analysis of correlated factors. World J Gastroenterol 2010; 16:2812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/3\">",
"      Hylander BI, Dalton CB, Castell DO, et al. Effect of intraperitoneal fluid volume changes on esophageal pressures: studies in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1991; 17:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/4\">",
"      Kim MJ, Kwon KH, Lee SW. Gastroesophageal reflux disease in CAPD patients. Adv Perit Dial 1998; 14:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/5\">",
"      Keshavarzian A, Iber FL, Vaeth J. Gastric emptying in patients with insulin-requiring diabetes mellitus. Am J Gastroenterol 1987; 82:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/6\">",
"      Brown-Cartwright D, Smith HJ, Feldman M. Gastric emptying of an indigestible solid in patients with end-stage renal disease on continuous ambulatory peritoneal dialysis. Gastroenterology 1988; 95:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/7\">",
"      Bird NJ, Streather CP, O'Doherty MJ, et al. Gastric emptying in patients with chronic renal failure on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1994; 9:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/8\">",
"      Fernstr&ouml;m A, Hylander B, Gryb&auml;ck P, et al. Gastric emptying and electrogastrography in patients on CAPD. Perit Dial Int 1999; 19:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/9\">",
"      Seibert DG, Moss AH, Holley JL, Foulks CJ. Intraperitoneal metoclopramide improves symptoms of gastroparesis in a CAPD patient. Perit Dial Int 1989; 9:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/10\">",
"      Moss, AH. Therapy for diabetic gastroparesis. Semin Dial 1991; 4:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/11\">",
"      Wadhwa NK, Atkins H, Cabralda T. Intraperitoneal erythromycin for gastroparesis. Ann Intern Med 1991; 114:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/12\">",
"      Gallar P, Oliet A, Vigil A, et al. Gastroparesis: an important cause of hospitalization in continuous ambulatory peritoneal dialysis patients and the role of erythromycin. Perit Dial Int 1993; 13 Suppl 2:S183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/13\">",
"      Amin K, Bastani B. Intraperitoneal ondansetron hydrochloride for intractable nausea and vomiting due to diabetic gastroparesis in a patient on peritoneal dialysis. Perit Dial Int 2002; 22:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/14\">",
"      Bargman JM. Complications of peritoneal dialysis related to increased intraabdominal pressure. Kidney Int Suppl 1993; 40:S75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/15\">",
"      Homodraka-Malis, A. Pathogenesis and treatment of back pain in peritoneal dialysis patients. Perit Dial Bull 1983; 3(Suppl 3):S41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/16\">",
"      Nomoto Y, Suga T, Nakajima K, et al. Acute hydrothorax in continuous ambulatory peritoneal dialysis--a collaborative study of 161 centers. Am J Nephrol 1989; 9:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/17\">",
"      Garc&iacute;a Ram&oacute;n R, Carrasco AM. Hydrothorax in peritoneal dialysis. Perit Dial Int 1998; 18:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/18\">",
"      Lew SQ. Hydrothorax: pleural effusion associated with peritoneal dialysis. Perit Dial Int 2010; 30:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/19\">",
"      Abraham, G, Shokker, A, Blake, P, Oreopoulos, DG. Massive hydrothorax in patients on peritoneal dialysis: A literature review. Adv Perit Dial 1988; 4:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/20\">",
"      Shemin D, Clark DD, Chazan JA. Unexplained pleural effusions in the peritoneal dialysis population. Perit Dial Int 1989; 9:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/21\">",
"      Fletcher S, Turney JH, Brownjohn AM. Increased incidence of hydrothorax complicating peritoneal dialysis in patients with adult polycystic kidney disease. Nephrol Dial Transplant 1994; 9:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/22\">",
"      Christidou F, Vayonas G. Recurrent acute hydrothorax in a CAPD patient: successful management with small volumes of dialysate. Perit Dial Int 1995; 15:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/23\">",
"      Simmons LE, Mir AR. A review of management of pleuroperitoneal communication in five CAPD patients. Adv Perit Dial 1989; 5:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/24\">",
"      Sudduth CD, Sahn SA. Pleurodesis for nonmalignant pleural effusions. Recommendations. Chest 1992; 102:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/25\">",
"      Hidai H, Takatsu S, Chiba T. Intrathoracic instillation of autologous blood in treating massive hydrothorax following CAPD. Perit Dial Int 1989; 9:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/26\">",
"      Kanaan N, Pieters T, Jamar F, Goffin E. Hydrothorax complicating continuous ambulatory peritoneal dialysis: successful management with talc pleurodesis under thoracoscopy. Nephrol Dial Transplant 1999; 14:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/27\">",
"      Szeto CC, Chow KM. Pathogenesis and management of hydrothorax complicating peritoneal dialysis. Curr Opin Pulm Med 2004; 10:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/28\">",
"      Pattison CW, Rodger RS, Adu D, et al. Surgical treatment of hydrothorax complicating continuous ambulatory peritoneal dialysis. Clin Nephrol 1984; 21:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/29\">",
"      Vaamonde CA, Michael UF, Metzger RA, Carroll KE Jr. Complications of acute peritoneal dialysis. J Chronic Dis 1975; 28:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/30\">",
"      Mactier RA, Sprosen TS, Gokal R, et al. Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int 1998; 53:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/31\">",
"      Bunchman TE, Ballal SH. Treatment of inflow pain by pH adjustment of dialysate in peritoneal dialysis. Perit Dial Int 1991; 11:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/32\">",
"      Tranaeus A. A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution--clinical benefits. The Bicarbonate/Lactate Study Group. Perit Dial Int 2000; 20:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/33\">",
"      Khan AN, Bernardini J, Johnston JR, Piraino B. Hypokalemia in peritoneal dialysis patients. Perit Dial Int 1996; 16:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/34\">",
"      Oreopoulos DG, Khanna R, Williams P, Vas SI. Continuous ambulatory peritoneal dialysis - 1981. Nephron 1982; 30:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/35\">",
"      Spital A, Sterns RH. Potassium supplementation via the dialysate in continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1985; 6:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/36\">",
"      Tziviskou E, Musso C, Bellizzi V, et al. Prevalence and pathogenesis of hypokalemia in patients on chronic peritoneal dialysis: one center's experience and review of the literature. Int Urol Nephrol 2003; 35:429.",
"     </a>",
"    </li>",
"    <li>",
"     Bargman, JM. Noninfectious complications of peritoneal dialysis. In: The Textbook of Peritoneal Dialysis, Gokal, R, Nolph, KD (Eds), Kluwer, Boston 1994. p.555.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/38\">",
"      Amirmokri P, Morgan P, Bastani B. Intra-peritoneal administration of potassium and magnesium: a practical method to supplement these electrolytes in peritoneal dialysis patients. Ren Fail 2007; 29:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/39\">",
"      Navarro JF, Mora C, Garc&iacute;a J, et al. Hypermagnesemia in CAPD. Relationship with parathyroid hormone levels. Perit Dial Int 1998; 18:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22904/abstract/40\">",
"      Hutchinson AJ. Serum magnesium and end-stage renal disease. Perit Dial Int 1997; 17:327.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1890 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8BB6C55152-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_23_22904=[""].join("\n");
var outline_f22_23_22904=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3409435\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GASTROESOPHAGEAL REFLUX DISEASE AND DELAYED GASTRIC EMPTYING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Gastroesophageal reflux disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Delayed gastric emptying",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      BACK PAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PLEURAL EFFUSION DUE TO PLEUROPERITONEAL LEAK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Clinical characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      HEMOPERITONEUM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PAIN ON DIALYSATE INFUSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ELECTROLYTE ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Magnesium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3409435\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41061?source=related_link\">",
"      Abdominal hernias in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1962?source=related_link\">",
"      Adequacy of peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16120?source=related_link\">",
"      Approach to the adult with nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18601?source=related_link\">",
"      Approach to the diagnosis and evaluation of low back pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24245?source=related_link\">",
"      Bloody peritoneal dialysate (hemoperitoneum)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13220?source=related_link\">",
"      Causes and treatment of hypermagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22617?source=related_link\">",
"      Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43209?source=related_link\">",
"      Etiology and diagnosis of delayed gastric emptying",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/29/37334?source=related_link\">",
"      Management of refractory nonmalignant pleural effusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41477?source=related_link\">",
"      Modalities for the diagnosis of abdominal and thoracic cavity defects in peritoneal dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7528?source=related_link\">",
"      Noninfectious complications of peritoneal dialysis catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9274?source=related_link\">",
"      Pathogenesis and treatment of malnutrition in maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14312?source=related_link\">",
"      Pathogenesis of delayed gastric emptying",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=related_link\">",
"      Pathogenesis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13928?source=related_link\">",
"      Pathophysiology of reflux esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/10/14501?source=related_link\">",
"      Patient information: Peritoneal dialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23337?source=related_link\">",
"      Problems with solute clearance and ultrafiltration in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/29/470?source=related_link\">",
"      Regulation of magnesium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32914?source=related_link\">",
"      Symptoms of hypermagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/21/13658?source=related_link\">",
"      Treatment of acute low back pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=related_link\">",
"      Treatment of delayed gastric emptying",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_23_22905="Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy";
var content_f22_23_22905=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/23/22905/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/23/22905/contributors\">",
"     Isaac Raijman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/23/22905/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/23/22905/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/23/22905/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/23/22905/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/23/22905/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Choledocholithiasis (a gallstone in the common bile duct) occurs in 15 to 20 percent of patients with cholelithiasis. The majority of gallstones form in the gallbladder and then pass into the common bile duct via the cystic duct. Common bile duct stones can also develop in patients who have an apparently normal gallbladder; such patients represent about 10 percent of those with choledocholithiasis. In addition, approximately 5 percent of patients who have undergone a cholecystectomy have a retained or recurrent stone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The introduction of endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic sphincterotomy in the late 1970s has virtually supplanted surgery for the treatment of this condition [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. This topic will review the most frequently used endoscopic techniques for common bile duct stone clearance (including sphincterotomy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    balloon dilation of the ampulla followed by stone extraction using baskets and extraction balloons) and mechanical lithotripsy. Other issues related to gallstones and their complications are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40936?source=see_link\">",
"     \"Approach to the patient with suspected choledocholithiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43557?source=see_link\">",
"     \"Endoscopic ultrasound in patients with suspected choledocholithiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39705?source=see_link\">",
"     \"Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/19/37175?source=see_link\">",
"     \"Endoscopic balloon dilatation for removal of bile duct stones\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6440?source=see_link\">",
"     \"Common bile duct exploration\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SPHINCTEROTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term sphincterotomy refers to severing of the deep muscle layers of the sphincter of Oddi. In contrast, papillotomy suggests cutting of the superficial papillary sphincter of the main duodenal papilla. However, in practice, these terms are used interchangeably.",
"   </p>",
"   <p>",
"    Sphincterotomy is the most commonly used therapy for treatment of choledocholithiasis. The goal of the sphincterotomy is to cut the biliary sphincter (",
"    <a class=\"graphic graphic_figure graphicRef78786 \" href=\"UTD.htm?27/17/27924\">",
"     figure 1",
"    </a>",
"    ), thereby eliminating the principal anatomic barrier impeding stone passage and facilitating stone extraction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2140989\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard sphincterotomy involves the application of electrocautery to create an incision through the musculature of the biliary portion of the sphincter of Oddi. A number of different devices are available with that vary in design to facilitate the procedure depending upon specific anatomic considerations. In expert hands, a sphincterotomy is possible in 95 to 100 percent of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/62/10214?source=see_link\">",
"     \"Standard biliary sphincterotomy technique: The cutting edge\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The length of the sphincterotomy should be tailored to the size of the stone and papilla. We prefer to create a sphincterotomy that completely unroofs the papilla, since this maximizes access to the common bile duct and decreases the risk of developing papillary stenosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12874?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sphincter of Oddi dysfunction\"",
"    </a>",
"    .) We use a standard Valleylab electrocautery unit (Tyco Healthcare Group, LP, Boulder CO) in a 2:1 cut:coagulation ratio. Typical power settings are 40 Watts in cut and 20 Watts in coagulation with a blend setting of 1 or 2. When using the ERBE apparatus (ERBE USA, Inc, Atlanta, GA), the machine provides automatic settings of 150 Watts in cut, and 25 to 35 Watts in coagulation.",
"   </p>",
"   <p>",
"    Sphincterotomy is usually performed after deep cannulation of the bile duct has been accomplished. However, in some circumstances, this may not be possible. As an example, impaction of a stone within the papillary sphincter may prohibit advancement of a papillotome or guidewire. In these patients, sphincterotomy can still be accomplished using a needle knife papillotome, a technique known as \"precutting\". (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/10/25767?source=see_link\">",
"     \"Precut (access) papillotomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common complication associated with endoscopic sphincterotomy is pancreatitis, which can also occur during ERCP without sphincterotomy. Other risks of sphincterotomy include those related to the endoscopy (such as complications of conscious sedation and esophageal perforation), perforation of the duodenum or bile duct, bleeding, and infection. The safety of endoscopic sphincterotomy depends upon a number of variables including coexisting medical illnesses, the indications for the sphincterotomy, and the endoscopist's experience. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39705?source=see_link\">",
"     \"Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Short-term complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-term complications related to biliary sphincterotomy (ie, immediately after or within 30 days of the procedure) occur in fewer than 10 percent of patients, as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, complications were observed in 112 of 1921 (6 percent) of patients at seven academic medical centers [",
"      <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/4\">",
"       4",
"      </a>",
"      ]. Two-thirds of the complications were considered to be mild (ie, requiring less than three days in the hospital).",
"     </li>",
"     <li>",
"      A slightly higher complication rate (10 percent) was observed in a multicenter study involving 2347 patients undergoing biliary sphincterotomy at 17 institutions in the United States and Canada [",
"      <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/5\">",
"       5",
"      </a>",
"      ]. The most frequent complications included pancreatitis (5 percent) and bleeding (2 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multivariate analysis identified two patient-related characteristics (suspected sphincter of Oddi dysfunction and the presence of cirrhosis) and three procedure-related characteristics (difficulty cannulating the bile duct, use of a precut sphincterotomy, and use of a combined percutaneous-endoscopic procedure) as independent risk factors for complications. Furthermore, endoscopists who performed more than one sphincterotomy per week had a significantly lower complication rate compared with endoscopists with less regular experience (8 versus 11 percent) and a lower rate of severe complications (0.9 versus 2.3 percent).",
"   </p>",
"   <p>",
"    In addition to the above risk factors for complications, other mostly anecdotal experience suggests that the risk of pancreatitis is increased in young women who have a non-dilated common bile duct (&lt;6 mm) and after multiple injections of the pancreatic duct or pancreatic duct acinarization (ie, injection of contrast sufficient to cause opacification of the terminal branches of the pancreatic ducts) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/6\">",
"     6",
"    </a>",
"    ]. On the other hand, the risk of pancreatitis may be decreased in patients with a dilated common bile duct due to gallstones and in those with a history of chronic pancreatitis. In addition, the prophylactic placement of a pancreatic stent may decrease the risk of pancreatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22983?source=see_link&amp;anchor=H3#H3\">",
"     \"Prophylactic pancreatic stents to prevent ERCP-induced pancreatitis: When do you use them?\", section on 'Prophylactic stenting'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A prior history of pancreatitis due to ERCP or other causes does not appear independently to increase the risk of complications. The management of pancreatitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7738?source=see_link\">",
"     \"Treatment of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most studies have found that the risk of bleeding after sphincterotomy is increased in patients who have a bleeding diathesis (including those on hemodialysis) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. In addition, the risk of bleeding is probably related to the size of the sphincterotomy, and may be increased after repeated procedures, extension of a previous sphincterotomy, and in patients with gallstones impacted in the ampulla [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Furthermore, in approximately 4 percent of patients, the retroduodenal artery courses through the region of the sphincterotomy, predisposing to severe hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Long-term complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term complications following endoscopic sphincterotomy include stone recurrence, papillary stenosis, and cholangitis, which occur in approximately 6 to 24 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Many endoscopists are particularly concerned about these complications in younger patients who will live for many years following sphincterotomy.",
"   </p>",
"   <p>",
"    This issue was evaluated in a review that included 94 patients younger than age 60 who were followed for a median of 15 years following biliary sphincterotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/12\">",
"     12",
"    </a>",
"    ]. Early complications occurred in 14 patients (15 percent), including one death due to retroperitoneal perforation. A total of 36 late complications were observed in 22 patients (24 percent), which included recurrent common bile duct stones in 13, combined with papillary stenosis in nine. Most complications were managed endoscopically or conservatively. One patient required surgery after failed endoscopic treatment, and one patient died of cholangitis before she could undergo ERCP.",
"   </p>",
"   <p>",
"    Another report addressing the same issues included 156 patients in whom long-term follow-up (average 10 years) was available [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/13\">",
"     13",
"    </a>",
"    ]. The majority of patients (88 percent) had no further biliary symptoms. However, recurrent biliary symptoms developed in 16 patients (10 percent); in nine of those cases, symptoms were potentially related to endoscopic sphincterotomy.",
"   </p>",
"   <p>",
"    In most reports, recurrent common bile duct stones occur most frequently in patients with concurrent choledocholithiasis and cholecystolithiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/10\">",
"     10",
"    </a>",
"    ]. As a result, it is preferable to perform a cholecystectomy following biliary sphincterotomy since the majority of stones form in the gallbladder.",
"   </p>",
"   <p>",
"    There has been a concern that sphincterotomy might increase the risk of biliary tract cancer by exposing the biliary tree to bacteria and other duodenal contents. A large registry study found an increased risk of malignancy in the bile ducts, liver, or pancreas in patients who underwent ERCP for apparent benign disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/14\">",
"     14",
"    </a>",
"    ]. However, the risk was not increased by sphincterotomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     High-risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the risk factors for complications discussed above, patients with comorbid illness are at greater risk for complications. Two relatively common settings are patients who have had a recent myocardial infarction and patients with cirrhosis (in whom the prevalence of gallstones is increased relative to the general population). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4489?source=see_link\">",
"     \"Epidemiology of and risk factors for gallstones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although the risk is increased, ERCP with sphincterotomy has been safely performed within several weeks after an acute myocardial infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/15\">",
"       15",
"      </a>",
"      ]. Stratification of risk depends upon a number of clinical factors that are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"       \"Estimation of cardiac risk prior to noncardiac surgery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The risk of biliary sphincterotomy in patients with cirrhosis was evaluated in a study that compared endoscopic therapy with surgery in 362 patients with choledocholithiasis complicated by acute obstructive suppurative cholangitis (group 1, 27 patients), cirrhosis (group 2, 12 patients), and patients who had neither disorder (group 3, 323 patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/16\">",
"       16",
"      </a>",
"      ]. In group 1, 3 of 17 patients treated emergently died (two had been treated surgically and one had been treated endoscopically). In group 2, two patients with Child class C cirrhosis died after elective sphincterotomy. Mortality was significantly higher in groups 1 and 2 compared with group 3 (11 and 17 versus 0.3 percent, respectively). Although not statistically significant, endoscopic treatment had a lower morbidity rate compared with surgery in group 1 (24 versus 67 percent) and group 2 (22 versus 67 percent). It is our opinion that these high-risk patients should be treated endoscopically.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Safety of outpatient sphincterotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing sphincterotomy traditionally were admitted to the hospital for overnight observation. However, increasing experience has demonstrated that the procedure can be safely performed in outpatients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. One study, for example, included 614 patients at 17 medical centers who were discharged on the same day following biliary sphincterotomy. Readmission to the hospital occurred in 35 patients (5.7 percent), the majority of whom had developed pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/18\">",
"     18",
"    </a>",
"    ]. Readmission was more likely in patients who had one or more risk factors that were identified in multivariate analysis (suspected sphincter of Oddi dysfunction, cirrhosis, difficult bile duct cannulation, precut sphincterotomy, or combined percutaneous-endoscopic procedure) compared with those without these risk factors (12 versus 4 percent). The majority of complications requiring readmission occurred within six hours of the procedure.",
"   </p>",
"   <p>",
"    The current standard of care for outpatients with choledocholithiasis is to discharge them from the endoscopy unit after one hour of observation. In our experience, the overwhelming majority do not require readmission. However, in patients at increased risk for complications (see",
"    <a class=\"local\" href=\"#H6\">",
"     'High-risk patients'",
"    </a>",
"    above), especially patients with cirrhosis or those in whom cannulation was difficult, we observe for longer or admit them to the hospital. For patients traveling a distance, we recommend an overnight stay in the city close to the hospital in the event that further intervention is necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Cholecystectomy following sphincterotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sphincterotomy is followed by cholecystectomy in most patients with symptomatic choledocholithiasis to eliminate the source of the majority of recurrent gallstones. However, in some clinical settings (such as in patients who are poor operative candidates), cholecystectomy may be undesirable.",
"   </p>",
"   <p>",
"    Studies evaluating the natural history of gallstone disease in patients who underwent sphincterotomy or endoscopic papillary balloon dilation without subsequent cholecystectomy suggest that recurrent gallstone-related disease occurs in 10 to 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/20-23\">",
"     20-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data suggest that prophylactic cholecystectomy should generally be offered to patients whose gallbladders remain in-situ after endoscopic sphincterotomy and clearance of common bile ducts stones. However, expectant management after biliary sphincterotomy in patients with the gallbladder in-situ may be appropriate for those at high risk for surgery from associated comorbidities, those unsuitable for surgery, or for elderly patients.",
"   </p>",
"   <p>",
"    A meta-analysis of five randomized trials (with a total of 662 patients) found that patients managed without cholecystectomy had significantly higher rates of recurrent biliary pain (RR 14.6, 95% CI 4.5-43), jaundice or cholangitis (RR 2.5, 95% CI 1.1-5.9), and need for repeat ERCP or other forms of cholangiography (RR 2.4, 95% CI 1.3-4.3) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/24\">",
"     24",
"    </a>",
"    ]. Cholecystectomy was eventually required in 35 percent of patients.",
"   </p>",
"   <p>",
"    Individual studies have shown the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One of the largest studies to examine this issue included 371 patients with symptomatic choledocholithiasis and cholecystolithiasis in whom the bile duct was clear following ERCP with sphincterotomy, but who did not undergo subsequent cholecystectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/20\">",
"       20",
"      </a>",
"      ]. During a mean follow-up of 7.7 years, cholecystitis and recurrence of choledocholithiasis were observed in 6 and 10 percent of patients, respectively. Recurrent choledocholithiasis was successfully treated endoscopically in all but one patient. The presence of pneumobilia and the need for lithotripsy were significantly associated with the recurrence of choledocholithiasis.",
"     </li>",
"     <li>",
"      Another study included a total of 178 patients (age &gt;60 years) who underwent sphincterotomy and were randomly assigned to immediate laparoscopic cholecystectomy or expectant management [",
"      <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/21\">",
"       21",
"      </a>",
"      ]. Median follow-up was approximately five years, during which time recurrent biliary events were significantly more likely in the expectant management group (24 versus 7 percent). Biliary events in the cholecystectomy group included cholangitis and biliary pain, while in the expectant management group included cholangitis, acute cholecystitis, biliary pain and jaundice.",
"     </li>",
"     <li>",
"      Another trial included 120 patients who had undergone sphincterotomy for common duct stones and were then randomly assigned to laparoscopic cholecystectomy or to watchful waiting [",
"      <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/22\">",
"       22",
"      </a>",
"      ]. During two-years of follow-up, recurrent biliary events were observed significantly more often in the group randomized to watchful waiting (47 versus 2 percent). At the end of the study, 37 percent of those originally assigned to watchful waiting had required cholecystectomy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The timing of cholecystectomy may also be important. Retrospective studies suggest that patients who undergo delayed cholecystectomy (more than two weeks after sphincterotomy) have higher conversion rates of laparoscopic procedures to open procedures compared with patients who undergo early cholecystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/25\">",
"     25",
"    </a>",
"    ]. Patients undergoing delayed cholecystectomy also appear to be at high risk of recurrent biliary events during the waiting period (20 percent in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a randomized controlled trial, 94 patients were assigned either to early laparoscopic cholecystectomy (within 72 hours of sphincterotomy) or delayed laparoscopic cholecystectomy (6 to 8 weeks after sphincterotomy) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/27\">",
"     27",
"    </a>",
"    ]. Patients who underwent early cholecystectomy had a lower rate of recurrent biliary events compared with those in the delayed cholecystectomy group (2 percent versus 36 percent). There were no differences between the groups with regard to conversion rates to open cholecystectomy (4 percent in the early group and 9 percent in the delayed group), operating times, difficulty of surgery, or length of hospital stay.",
"   </p>",
"   <p>",
"    Other nonsurgical options for treatment of gallstone-related disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6408?source=see_link\">",
"     \"Dissolution therapy for the treatment of gallstones\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PAPILLARY BALLOON DILATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of concern regarding long-term complications related to biliary sphincterotomy (particularly in young patients), extraction of common bile duct stones while preserving the biliary sphincter has been attempted. One technique involves dilation of the ampulla with a balloon followed by stone extraction. Endoscopic balloon dilation has been evaluated in a number of studies. However, its safety has been questioned. Until more data are available, endoscopic sphincterotomy is the method of choice for the treatment of choledocholithiasis. However, combining large balloon dilation with small sphincterotomy appears to be safe and permits stone extraction while avoiding the need for mechanical lithotripsy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. In a randomized trial with 156 patients, those who underwent balloon dilation following a limited sphincterotomy had similar stone clearance rates as those who underwent standard endoscopic sphincterotomy (89 percent for both groups) and similar complication rates (7 versus 10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/30\">",
"     30",
"    </a>",
"    ]. However, patients in the limited sphincterotomy with balloon dilation group had lower rates of mechanical lithotripsy (29 versus 46 percent) and lower hospital costs ($5025 versus $6005). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/19/37175?source=see_link\">",
"     \"Endoscopic balloon dilatation for removal of bile duct stones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of large balloons to remove biliary stones of various sizes has been a common practice for years. However, questions of duration of the balloon dilation, balloon size, and risks associated with balloon dilation have largely remained unanswered. Available studies have shown the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 70 patients undergoing an endoscopic removal of bile duct stones using balloons, patients were assigned to 60 seconds (conventional) or 20 seconds (short) of balloon inflation [",
"      <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/31\">",
"       31",
"      </a>",
"      ]. The conventional and short groups did not differ with regard to clearance rate (94 versus 97 percent) or in their requirement for mechanical lithotripsy (97 versus 100 percent). There was a trend toward an increased rate of pancreatitis in the conventional group (11 versus 6 percent), but the result did not attain statistical significance.",
"     </li>",
"     <li>",
"      A randomized controlled trial examined 170 patients undergoing endoscopic removal of bile duct stones using balloon sphincteroplasty [",
"      <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/32\">",
"       32",
"      </a>",
"      ]. Patients were assigned to one-minute balloon dilation or five-minute balloon dilation using a 10 mm balloon. Successful stone extraction was more common in the five-minute group than in the one-minute group (93 versus 80 percent). Pancreatitis was less common in the five-minute group than in the one-minute group (5 versus 15 percent). The authors postulated that the increased rate of pancreatitis in the one-minute group may be due to a compartment syndrome at the level of the ampulla that results in significant local edema and compression.",
"     </li>",
"     <li>",
"      A randomized trial compared sphincterotomy and balloon dilation in 282 patients with common bile duct stones [",
"      <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/33\">",
"       33",
"      </a>",
"      ]. The trial found that after a median of 6.7 years follow-up, patients who underwent sphincterotomy had more late biliary complications than patients who underwent balloon dilation (25 versus 10 percent). Complications included recurrent stones, cholangitis without stone recurrence, cholecystitis, and one case of gallbladder cancer. However, in an earlier report from the same trial, it was noted that patients who underwent balloon dilation had a significantly higher rate of post-procedure pancreatitis (11 versus 3 percent), though the overall rate of early complications was similar between those who were treated with balloon dilation and those treated with sphincterotomy (15 versus 12 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     BASKETS AND EXTRACTING BALLOONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following endoscopic sphincterotomy or balloon dilation, devices may be needed to extract common bile duct stones. Most stones less than 1 cm (and some even larger) will pass spontaneously.",
"   </p>",
"   <p>",
"    The most common tools used to extract stones are balloons and baskets. These devices are available in multiple shapes and sizes and have a variety of characteristics that may be preferentially suited to particular anatomic variations or stone characteristics.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We usually choose a basket when the duct is dilated or multiple stones larger are present. A problem with using balloons in dilated ducts or when the stone is impacted is that the balloon may simply squeeze between the stone and the wall.",
"     </li>",
"     <li>",
"      We typically use a balloon the duct is not dilated or if there is a single free-floating stone. We choose a balloon that closely approximates or is larger than the diameter of the duct. Balloons are also useful when multiple small stones are present or when a larger stone has been crushed (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef60642 \" href=\"UTD.htm?8/60/9153\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once a stone has been grasped within a basket or a balloon has been advanced proximal to the stone, pulling the",
"    <span class=\"nowrap\">",
"     stone/balloon",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     stone/basket",
"    </span>",
"    apparatus is often sufficient to extract the stone. However, in many instances, resistance is encountered when the stone reaches the ampulla, particularly if the sphincterotomy is smaller than the stone's diameter. Greater mechanical advantage can be obtained by turning the small wheel of the endoscope to the right and pushing the endoscope further in the stomach (ie, the long position), which straightens the bile duct axis. If more force is needed, the left hand can be flexed while grasping the endoscope and turning the body toward the right, which forces the endoscope into an even straighter position.",
"   </p>",
"   <p>",
"    One risk of basket extraction is impaction of the basket within the bile duct. This results from imbedding of the basket's wires within the stone surface. As a result, the basket may not be removable from the stone, which anchors the basket within the bile duct. Furthermore, once the basket has become impacted, it may not be possible to regain access to the bile duct to perform additional therapeutic maneuvers. Mechanical lithotripsy is often helpful in these circumstances. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Mechanical lithotripsy'",
"    </a>",
"    below.) However, in extreme cases, surgery may be required to remove the basket.",
"   </p>",
"   <p>",
"    The risk of impaction can be reduced by extraction of the most distal stone (ie, the one closest to the ampulla) first when multiple stones are present. Beginning with proximal stones risks creating a \"traffic jam\" as the captured stone is pulled through the remaining gallstones. The risk of impaction can also be reduced by gently pulling the basket and stone to the preampullary level without closing the basket tightly against the stone. Suction and steady force can then be applied to extract the stone using the methods to improve mechanical advantage discussed above. However, care should be taken to avoid perforation of the opposite duodenal wall by the endoscope (especially if a considerable amount of force is required), since the bend in the endoscope pushes against the duodenal wall during straightening.",
"   </p>",
"   <p>",
"    Some authorities have used sublingual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/35\">",
"     35",
"    </a>",
"    ] or an infusion of isosorbide [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/36\">",
"     36",
"    </a>",
"    ] to relax the sphincter of Oddi and facilitate stone extraction. However, only a small number of patients have been studied, and the benefit of giving these medications is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MECHANICAL LITHOTRIPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical lithotripsy is most often used when the standard methods of stone extraction fail. Mechanical lithotriptors are devices that are designed to break stones that have been captured within a basket. Several lithotriptors are commercially available, including devices that can be passed through the endoscope, devices that can be used only after the endoscope has been removed from the patient, and hybrid-type devices that combine out-of-the-scope and inside-the-scope principles.",
"   </p>",
"   <p>",
"    Most experience with through-the-endoscope lithotriptors has been with the Olympus lithotriptors BML-3Q and BML-4Q (Olympus Corp, Tokyo, Japan). These lithotriptors are reusable, but cumbersome to assemble and somewhat difficult to use. The larger model is stiffer, making ductal cannulation problematic. By comparison, many of the newer lithotriptors are disposable, more flexible, preassembled, and easier to use with better handles. These lithotriptors can be used with stones located anywhere in the biliary tree as long as the stone can be grasped.",
"   </p>",
"   <p>",
"    The out-of-the-scope devices are used once a stone has been trapped within a standard basket. The outer sheath of the basket is either cut or disassembled, and the basket wire is then introduced through the metallic sheath of the lithotriptor. Cranking of the lithotriptor forces the metallic sheath to move forward until it reaches the stone causing tightening; the resulting pressure fragments the stone (",
"    <a class=\"graphic graphic_picture graphicRef59349 \" href=\"UTD.htm?36/1/36881\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The out-of-the-scope lithotriptors require the stone to be at the ampullary level and their use is contraindicated for more proximal stones (unless they can be dragged to an ampullary location) since ductal rupture can occur. In addition, it is very important that after the bare basket is wound in the handle, a loop inside the stomach be formed with the metallic sheath to permit straightening of the lithotriptor cable upon stone fragmentation. Failure to do this can lead to gastric lacerations. Once the stone is fragmented, the basket is removed and the smaller stones are extracted using standard techniques. A small mucosal laceration at the roof of the papilla or at the papillotomy site may be noted but is of uncertain clinical significance.",
"   </p>",
"   <p>",
"    The overall success rate for ductal clearance with mechanical lithotripsy is 80 to 90 percent, although 20 to 30 percent of patients require more than one session [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/37-46\">",
"     37-46",
"    </a>",
"    ]. Failure is most often due to impaction of the stone in the bile duct [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/45\">",
"     45",
"    </a>",
"    ]. Complications directly related to the lithotripsy are uncommon. A large series from expert centers in the United States with over 600 cases reported that only 3.5 percent of biliary cases experienced complications, mainly from broken or trapped baskets. Most could be resolved without surgery by extending the sphincterotomy or using electrohydraulic lithotripsy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The through-the-scope lithotriptor overcomes some of the disadvantages of out-of-scope lithotriptors discussed above. Experience with one of these devices (Monolith lithotriptor, Microvasive Corp, Natick, MA) was illustrated in a series of 20 patients who had gallstones ranging in size from 10 to 30 mm; 16 of the patients had multiple stones (median of five) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/42\">",
"     42",
"    </a>",
"    ]. Cannulation with the lithotriptor was successful in all patients, although some patients required multiple attempts to intubate the bile duct. The overall success rate to capture, fragment, and completely clear the bile duct was 80 percent. The basket was misshapen in 14 patients (although some stones could still be crushed) and deployment failed in one due to a large stone. Compared with the out-of-scope lithotriptors, the through-the-scope lithotriptors are better suited for stones that are impacted above the level of the ampulla.",
"   </p>",
"   <p>",
"    Another series described experience with a different through-the-scope lithotripter (Olympus BML-4Q) in 304 patients with difficult bile duct stones [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/46\">",
"     46",
"    </a>",
"    ]. Successful stone clearance was accomplished in 90 percent of patients. Most patients required only one session for stone clearance. Surgery was required in 32 patients in whom lithotripsy was unsuccessful. Complications included cholangitis in eight, pancreatitis in 21, and bleeding in 10. There was no mortality. The complication rate was greater in patients who required multiple sessions for stone clearance.",
"   </p>",
"   <p>",
"    In a randomized trial of 90 patients with large bile duct stones, large balloon dilation was compared with mechanical lithotripsy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/48\">",
"     48",
"    </a>",
"    ]. A large bile duct stone was defined as any stone larger than 12 mm. Complete stone removal was possible in 98 percent of patients undergoing balloon dilation compared with 91 percent of those treated with mechanical lithotripsy, but the difference was not statistically significant. Post-procedure cholangitis was more common in the patients treated with mechanical lithotripsy compared with those treated with balloon dilation (13 versus 0 percent). Post-procedure pancreatitis and bleeding each occurred in 2 percent of the patients, with equal distribution between the groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extracorporeal shock wave lithotripsy (ESWL) has been used for the treatment of pancreatic stones and of gallstones within the gallbladder. It also offers an alternative in patients with bile duct stones that cannot be removed by the endoscopic methods described above [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/49-53\">",
"     49-53",
"    </a>",
"    ]. One report focused on 313 of 1587 consecutive patients in whom endoscopic stone extraction was unsuccessful [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22905/abstract/53\">",
"     53",
"    </a>",
"    ]. Complete clearance of bile duct calculi was achieved in 281 patients (90 percent) using ESWL. Complications (including cholangitis and acute cholecystitis) were rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2141388\">",
"    <span class=\"h1\">",
"     ELECTROHYDRAULIC LITHOTRIPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrohydraulic lithotripsy can be performed in conjunction with peroral, percutaneous, or intraoperative choledochoscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12854?source=see_link\">",
"     \"Electrohydraulic lithotripsy in the treatment of bile and pancreatic duct stones\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21897?source=see_link\">",
"     \"Cholangioscopy and pancreatoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18166?source=see_link\">",
"     \"Percutaneous transhepatic cholangioscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6440?source=see_link\">",
"     \"Common bile duct exploration\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6562800\">",
"    <span class=\"h1\">",
"     LASER LITHOTRIPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lithotripsy can also be accomplished using laser light. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16856?source=see_link\">",
"     \"Laser lithotripsy for the treatment of gallstones\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/29/8658?source=see_link\">",
"       \"Patient information: Gallstones (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/56/1923?source=see_link\">",
"       \"Patient information: Gallbladder removal (cholecystectomy) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/21/7507?source=see_link\">",
"       \"Patient information: Gallstones (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2140851\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic techniques for common bile duct stone clearance include sphincterotomy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    balloon dilation of the ampulla followed by stone extraction using baskets and extraction balloons as well as mechanical lithotripsy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sphincterotomy is the most commonly used therapy for treatment of choledocholithiasis. The goal of the sphincterotomy is to cut the biliary sphincter (",
"      <a class=\"graphic graphic_figure graphicRef78786 \" href=\"UTD.htm?27/17/27924\">",
"       figure 1",
"      </a>",
"      ), thereby eliminating the principal anatomic barrier impeding stone passage and facilitating stone extraction. Standard sphincterotomy involves the application of electrocautery to create an incision through the musculature of the biliary portion of the sphincter of Oddi. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Sphincterotomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common complication associated with endoscopic sphincterotomy is pancreatitis. Other risks of sphincterotomy include those related to the endoscopy (such as complications of conscious sedation and esophageal perforation), perforation of the duodenum or bile duct, bleeding, and infection. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Safety'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of concern regarding long-term complications related to biliary sphincterotomy, extraction of common bile duct stones while preserving the biliary sphincter has been attempted. One technique involves dilation of the ampulla with a balloon followed by stone extraction. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Papillary balloon dilation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following endoscopic sphincterotomy or balloon dilation, devices may be needed to extract common bile duct stones. The most common tools used to extract stones are balloons and baskets. These devices are available in multiple shapes and sizes and have a variety of characteristics that may be preferentially suited to particular anatomic variations or stone characteristics. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Baskets and extracting balloons'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mechanical lithotripsy is most often used when the standard methods of stone extraction fail. Mechanical lithotriptors are designed to break stones that have been captured within a basket. Several lithotriptors are commercially available, including devices that can be passed through the endoscope, devices that can be used only after the endoscope has been removed from the patient, and hybrid-type devices that combine out-of-the-scope and inside-the-scope principles. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Mechanical lithotripsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alternative methods for the removal of common bile duct stones are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12854?source=see_link\">",
"       \"Electrohydraulic lithotripsy in the treatment of bile and pancreatic duct stones\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6440?source=see_link\">",
"       \"Common bile duct exploration\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/1\">",
"      Hermann RE. The spectrum of biliary stone disease. Am J Surg 1989; 158:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/2\">",
"      Kawai K, Akasaka Y, Murakami K, et al. Endoscopic sphincterotomy of the ampulla of Vater. Gastrointest Endosc 1974; 20:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/3\">",
"      Classen M, Demling L. [Endoscopic sphincterotomy of the papilla of vater and extraction of stones from the choledochal duct (author's transl)]. Dtsch Med Wochenschr 1974; 99:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/4\">",
"      Cotton PB, Geenen JE, Sherman S, et al. Endoscopic sphincterotomy for stones by experts is safe, even in younger patients with normal ducts. Ann Surg 1998; 227:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/5\">",
"      Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/6\">",
"      Mehta SN, Pavone E, Barkun JS, et al. Predictors of post-ERCP complications in patients with suspected choledocholithiasis. Endoscopy 1998; 30:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/7\">",
"      Nelson DB, Freeman ML. Major hemorrhage from endoscopic sphincterotomy: risk factor analysis. J Clin Gastroenterol 1994; 19:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/8\">",
"      Leung JW, Chan FK, Sung JJ, Chung S. Endoscopic sphincterotomy-induced hemorrhage: a study of risk factors and the role of epinephrine injection. Gastrointest Endosc 1995; 42:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/9\">",
"      Goodall RJ. Bleeding after endoscopic sphincterotomy. Ann R Coll Surg Engl 1985; 67:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/10\">",
"      Wojtun S, Gil J, Gietka W, Gil M. Endoscopic sphincterotomy for choledocholithiasis: a prospective single-center study on the short-term and long-term treatment results in 483 patients. Endoscopy 1997; 29:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/11\">",
"      Hawes RH, Cotton PB, Vallon AG. Follow-up 6 to 11 years after duodenoscopic sphincterotomy for stones in patients with prior cholecystectomy. Gastroenterology 1990; 98:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/12\">",
"      Bergman JJ, van der Mey S, Rauws EA, et al. Long-term follow-up after endoscopic sphincterotomy for bile duct stones in patients younger than 60 years of age. Gastrointest Endosc 1996; 44:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/13\">",
"      Prat F, Malak NA, Pelletier G, et al. Biliary symptoms and complications more than 8 years after endoscopic sphincterotomy for choledocholithiasis. Gastroenterology 1996; 110:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/14\">",
"      Str&ouml;mberg C, Luo J, Enochsson L, et al. Endoscopic sphincterotomy and risk of malignancy in the bile ducts, liver, and pancreas. Clin Gastroenterol Hepatol 2008; 6:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/15\">",
"      Cappell MS. Endoscopic retrograde cholangiopancreatography with endoscopic sphincterotomy for symptomatic choledocholithiasis after recent myocardial infarction. Am J Gastroenterol 1996; 91:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/16\">",
"      Chijiiwa K, Kozaki N, Naito T, et al. Treatment of choice for choledocholithiasis in patients with acute obstructive suppurative cholangitis and liver cirrhosis. Am J Surg 1995; 170:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/17\">",
"      Elfant AB, Bourke MJ, Alhalel R, et al. A prospective study of the safety of endoscopic therapy for choledocholithiasis in an outpatient population. Am J Gastroenterol 1996; 91:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/18\">",
"      Freeman ML, Nelson DB, Sherman S, et al. Same-day discharge after endoscopic biliary sphincterotomy: observations from a prospective multicenter complication study. The Multicenter Endoscopic Sphincterotomy (MESH) Study Group. Gastrointest Endosc 1999; 49:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/19\">",
"      Ho KY, Montes H, Sossenheimer MJ, et al. Features that may predict hospital admission following outpatient therapeutic ERCP. Gastrointest Endosc 1999; 49:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/20\">",
"      Saito M, Tsuyuguchi T, Yamaguchi T, et al. Long-term outcome of endoscopic papillotomy for choledocholithiasis with cholecystolithiasis. Gastrointest Endosc 2000; 51:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/21\">",
"      Lau JY, Leow CK, Fung TM, et al. Cholecystectomy or gallbladder in situ after endoscopic sphincterotomy and bile duct stone removal in Chinese patients. Gastroenterology 2006; 130:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/22\">",
"      Boerma D, Rauws EA, Keulemans YC, et al. Wait-and-see policy or laparoscopic cholecystectomy after endoscopic sphincterotomy for bile-duct stones: a randomised trial. Lancet 2002; 360:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/23\">",
"      Tsujino T, Kawabe T, Komatsu Y, et al. Endoscopic papillary balloon dilation for bile duct stone: immediate and long-term outcomes in 1000 patients. Clin Gastroenterol Hepatol 2007; 5:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/24\">",
"      McAlister VC, Davenport E, Renouf E. Cholecystectomy deferral in patients with endoscopic sphincterotomy. Cochrane Database Syst Rev 2007; :CD006233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/25\">",
"      de Vries A, Donkervoort SC, van Geloven AA, Pierik EG. Conversion rate of laparoscopic cholecystectomy after endoscopic retrograde cholangiography in the treatment of choledocholithiasis: does the time interval matter? Surg Endosc 2005; 19:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/26\">",
"      Schiphorst AH, Besselink MG, Boerma D, et al. Timing of cholecystectomy after endoscopic sphincterotomy for common bile duct stones. Surg Endosc 2008; 22:2046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/27\">",
"      Reinders JS, Goud A, Timmer R, et al. Early laparoscopic cholecystectomy improves outcomes after endoscopic sphincterotomy for choledochocystolithiasis. Gastroenterology 2010; 138:2315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/28\">",
"      Ersoz G, Tekesin O, Ozutemiz AO, Gunsar F. Biliary sphincterotomy plus dilation with a large balloon for bile duct stones that are difficult to extract. Gastrointest Endosc 2003; 57:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/29\">",
"      Minami A, Hirose S, Nomoto T, Hayakawa S. Small sphincterotomy combined with papillary dilation with large balloon permits retrieval of large stones without mechanical lithotripsy. World J Gastroenterol 2007; 13:2179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/30\">",
"      Teoh AY, Cheung FK, Hu B, et al. Randomized Trial of Endoscopic Sphincterotomy With Balloon Dilation Versus Endoscopic Sphincterotomy Alone for Removal of Bile Duct Stones. Gastroenterology 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/31\">",
"      Bang BW, Jeong S, Lee DH, et al. The ballooning time in endoscopic papillary balloon dilation for the treatment of bile duct stones. Korean J Intern Med 2010; 25:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/32\">",
"      Liao WC, Lee CT, Chang CY, et al. Randomized trial of 1-minute versus 5-minute endoscopic balloon dilation for extraction of bile duct stones. Gastrointest Endosc 2010; 72:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/33\">",
"      Yasuda I, Fujita N, Maguchi H, et al. Long-term outcomes after endoscopic sphincterotomy versus endoscopic papillary balloon dilation for bile duct stones. Gastrointest Endosc 2010; 72:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/34\">",
"      Fujita N, Maguchi H, Komatsu Y, et al. Endoscopic sphincterotomy and endoscopic papillary balloon dilatation for bile duct stones: A prospective randomized controlled multicenter trial. Gastrointest Endosc 2003; 57:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/35\">",
"      Uchida N, Ezaki T, Hirabayashi S, et al. Endoscopic lithotomy of common bile duct stones with sublingual nitroglycerin and guidewire. Am J Gastroenterol 1997; 92:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/36\">",
"      Minami A, Maeta T, Kohi F, et al. Endoscopic papillary dilation by balloon and isosorbide dinitrate drip infusion for removing bile duct stone. Scand J Gastroenterol 1998; 33:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/37\">",
"      Shaw MJ, Mackie RD, Moore JP, et al. Results of a multicenter trial using a mechanical lithotripter for the treatment of large bile duct stones. Am J Gastroenterol 1993; 88:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/38\">",
"      Shaw MJ, Dorsher PJ, Vennes JA. A new mechanical lithotripter for the treatment of large common bile duct stones. Am J Gastroenterol 1990; 85:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/39\">",
"      Hintze RE, Adler A, Veltzke W. Outcome of mechanical lithotripsy of bile duct stones in an unselected series of 704 patients. Hepatogastroenterology 1996; 43:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/40\">",
"      Van Dam J, Sivak MV Jr. Mechanical lithotripsy of large common bile duct stones. Cleve Clin J Med 1993; 60:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/41\">",
"      Siegel JH, Ben-Zvi JS, Pullano WE. Mechanical lithotripsy of common duct stones. Gastrointest Endosc 1990; 36:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/42\">",
"      Sorbi D, Van Os EC, Aberger FJ, et al. Clinical application of a new disposable lithotripter: a prospective multicenter study. Gastrointest Endosc 1999; 49:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/43\">",
"      Cipolletta L, Costamagna G, Bianco MA, et al. Endoscopic mechanical lithotripsy of difficult common bile duct stones. Br J Surg 1997; 84:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/44\">",
"      Cohello R, Bordas JM, Guevara MC, et al. [Mechanical lithotripsy during retrograde cholangiography in choledocholithiasis untreatable by conventional endoscopic sphincterotomy]. Gastroenterol Hepatol 1997; 20:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/45\">",
"      Garg PK, Tandon RK, Ahuja V, et al. Predictors of unsuccessful mechanical lithotripsy and endoscopic clearance of large bile duct stones. Gastrointest Endosc 2004; 59:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/46\">",
"      Chang WH, Chu CH, Wang TE, et al. Outcome of simple use of mechanical lithotripsy of difficult common bile duct stones. World J Gastroenterol 2005; 11:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/47\">",
"      Thomas M, Howell DA, Carr-Locke D, et al. Mechanical lithotripsy of pancreatic and biliary stones: complications and available treatment options collected from expert centers. Am J Gastroenterol 2007; 102:1896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/48\">",
"      Stefanidis G, Viazis N, Pleskow D, et al. Large balloon dilation vs. mechanical lithotripsy for the management of large bile duct stones: a prospective randomized study. Am J Gastroenterol 2011; 106:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/49\">",
"      Sauerbruch T, Stern M. Fragmentation of bile duct stones by extracorporeal shock waves. A new approach to biliary calculi after failure of routine endoscopic measures. Gastroenterology 1989; 96:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/50\">",
"      Sauerbruch T, Holl J, Sackmann M, Paumgartner G. Fragmentation of bile duct stones by extracorporeal shock-wave lithotripsy: a five-year experience. Hepatology 1992; 15:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/51\">",
"      Jakobs R, Adamek HE, Maier M, et al. Fluoroscopically guided laser lithotripsy versus extracorporeal shock wave lithotripsy for retained bile duct stones: a prospective randomised study. Gut 1997; 40:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/52\">",
"      Neuhaus H, Zillinger C, Born P, et al. Randomized study of intracorporeal laser lithotripsy versus extracorporeal shock-wave lithotripsy for difficult bile duct stones. Gastrointest Endosc 1998; 47:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22905/abstract/53\">",
"      Sackmann M, Holl J, Sauter GH, et al. Extracorporeal shock wave lithotripsy for clearance of bile duct stones resistant to endoscopic extraction. Gastrointest Endosc 2001; 53:27.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 674 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.167.4.114-2B3BC00349-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_23_22905=[""].join("\n");
var outline_f22_23_22905=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2140851\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SPHINCTEROTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2140989\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Safety",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Short-term complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Long-term complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - High-risk patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Safety of outpatient sphincterotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Cholecystectomy following sphincterotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PAPILLARY BALLOON DILATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      BASKETS AND EXTRACTING BALLOONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MECHANICAL LITHOTRIPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2141388\">",
"      ELECTROHYDRAULIC LITHOTRIPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6562800\">",
"      LASER LITHOTRIPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2140851\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/674\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/674|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/60/9153\" title=\"diagnostic image 1\">",
"      Balloon extraction of common bile duct stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/674|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/17/27924\" title=\"figure 1\">",
"      Sphincter of Oddi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/674|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/1/36881\" title=\"picture 1\">",
"      Out of scope lithotriptor",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40936?source=related_link\">",
"      Approach to the patient with suspected choledocholithiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21897?source=related_link\">",
"      Cholangioscopy and pancreatoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12874?source=related_link\">",
"      Clinical manifestations and diagnosis of sphincter of Oddi dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6440?source=related_link\">",
"      Common bile duct exploration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6408?source=related_link\">",
"      Dissolution therapy for the treatment of gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12854?source=related_link\">",
"      Electrohydraulic lithotripsy in the treatment of bile and pancreatic duct stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/19/37175?source=related_link\">",
"      Endoscopic balloon dilatation for removal of bile duct stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43557?source=related_link\">",
"      Endoscopic ultrasound in patients with suspected choledocholithiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4489?source=related_link\">",
"      Epidemiology of and risk factors for gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16856?source=related_link\">",
"      Laser lithotripsy for the treatment of gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39705?source=related_link\">",
"      Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/56/1923?source=related_link\">",
"      Patient information: Gallbladder removal (cholecystectomy) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/21/7507?source=related_link\">",
"      Patient information: Gallstones (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/29/8658?source=related_link\">",
"      Patient information: Gallstones (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18166?source=related_link\">",
"      Percutaneous transhepatic cholangioscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/10/25767?source=related_link\">",
"      Precut (access) papillotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22983?source=related_link\">",
"      Prophylactic pancreatic stents to prevent ERCP-induced pancreatitis: When do you use them?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/62/10214?source=related_link\">",
"      Standard biliary sphincterotomy technique: The cutting edge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7738?source=related_link\">",
"      Treatment of acute pancreatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_23_22906="Diagnosis of fetal growth restriction";
var content_f22_23_22906=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of fetal growth restriction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/23/22906/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/23/22906/contributors\">",
"     Michael Y Divon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/23/22906/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/23/22906/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/23/22906/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/23/22906/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/23/22906/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major focus of prenatal care is to determine whether a fetus is at risk for growth restriction and to identify the growth restricted fetus. Fetal growth is important because there is an inverse relationship between the",
"    <span class=\"nowrap\">",
"     fetal/neonatal",
"    </span>",
"    weight percentile and adverse perinatal outcome, with the greatest risk at weights below the third percentile for gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In addition, fetal growth restriction appears to be an antecedent to some cases of hypertension, hyperlipidemia, coronary heart disease, and diabetes mellitus in the adult (Barker hypothesis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9593?source=see_link\">",
"     \"Small for gestational age infant\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39477?source=see_link\">",
"     \"Possible role of low birth weight in the pathogenesis of essential hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prenatal screening for fetal growth restriction (FGR) in general obstetrical populations involves identifying risk factors for impaired fetal growth and physically assessing fetal size. Clinical suspicion based upon risk factors or physical examination is followed by a detailed sonographic assessment of the fetus, placenta, and amniotic fluid. The most common sonography-based definition of FGR is a weight below the 10th percentile for gestational age, although other definitions employing a variety of criteria have been advocated. This definition is controversial because it does not make a distinction among fetuses who are constitutionally small, growth restricted and small, and growth restricted but not small (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Definition'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The goal of prenatal detection of fetuses that are small is to reduce the morbidity and mortality associated with this problem by employing some intervention. Although stillbirth rates are higher when FGR is not detected antenatally [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/3\">",
"     3",
"    </a>",
"    ], there is only low quality evidence that antenatal identification of FGR improves outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/4\">",
"     4",
"    </a>",
"    ]. Unfortunately, significant problems remain in terms of defining the population of growth restricted fetuses at high risk of adverse outcome, accurately identifying these fetuses in utero, and determining interventions to improve outcome. These issues need to be addressed by large multicenter studies employing consistent definitions, randomly assigned interventions, and with long-term follow-up.",
"   </p>",
"   <p>",
"    The diagnosis of FGR will be reviewed here. The etiology, management, and prognosis of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10616?source=see_link\">",
"     \"Overview of causes of and risk factors for fetal growth restriction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23994?source=see_link\">",
"     \"Fetal growth restriction: Evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9593?source=see_link\">",
"     \"Small for gestational age infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common definition of FGR refers to a weight below the 10th percentile for gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/5\">",
"     5",
"    </a>",
"    ], although other definitions employing a variety of criteria have been advocated (eg, &lt;5th percentile, &lt;3rd percentile) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. This definition is problematic because it does not make a distinction among fetuses who are constitutionally small, small because a pathologic process has kept them from achieving their genetic growth potential, and not small but a pathologic process has kept them from achieving their genetic growth potential. It also requires an appropriate reference standard (",
"    <a class=\"graphic graphic_table graphicRef75060 \" href=\"UTD.htm?2/30/2541\">",
"     table 1",
"    </a>",
"    ). Whether this standard should be based on birth weights across gestation, ultrasound-estimated fetal weights across gestation, or a customized standard, is also controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/8\">",
"     8",
"    </a>",
"    ]. The major criticism of the birth weight reference is that before term it is flawed because babies born preterm are often growth restricted. The ultrasound-based approach is limited by the inaccuracy and imprecision of ultrasound estimated fetal weight.",
"   </p>",
"   <p>",
"    A small for gestational age (SGA) infant may be growth restricted or constitutionally small. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9593?source=see_link\">",
"     \"Small for gestational age infant\"",
"    </a>",
"    .) As many as 70 percent of fetuses who are estimated to weigh below the 10th percentile for gestational age are small simply due to constitutional factors such as female sex (",
"    <a class=\"graphic graphic_table graphicRef75060 \" href=\"UTD.htm?2/30/2541\">",
"     table 1",
"    </a>",
"    ) or maternal ethnicity, parity, or body mass index; they are not at high risk of perinatal mortality and morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/9\">",
"     9",
"    </a>",
"    ]. There is a real possibility of misclassifying these normally nourished, healthy, but constitutionally small, fetuses as growth restricted. By comparison, a malnourished fetus whose estimated weight is slightly greater than the 10th percentile may be misclassified as appropriately grown and at low risk of adverse perinatal outcome, even though its weight may be far below its genetic potential.",
"   </p>",
"   <p>",
"    Numerous approaches to differentiate the fetus or infant with growth restriction from the small, but otherwise healthy, baby have been proposed. Some criteria pertain to the fetus, others can only be employed in the neonate (eg, ponderal index, skin fold thickness, presence of nucleated red blood cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/10\">",
"     10",
"    </a>",
"    ]).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NORMAL AND ABNORMAL FETAL GROWTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal fetal growth reflects the interaction of the fetus's genetically predetermined growth potential and its modulation by the health of the fetus, placenta and the mother.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Normal growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;The process of fetal growth comprises three consecutive and somewhat overlapping phases. The first phase is the phase of cellular hyperplasia and encompasses the first 16 weeks of gestation. The second phase, known as the phase of concomitant hyperplasia and hypertrophy, occurs between the 16th and 32nd weeks and involves increases in cell size and number. The third and final phase, called the phase of cellular hypertrophy, occurs between the 32nd week and term and is characterized by a rapid increase in cell size.",
"   </p>",
"   <p>",
"    Quantitatively, normal singleton fetal growth increases from approximately 5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    at 14 to 15 weeks of gestation to 10",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    at 20 weeks and 30 to 35",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    at 32 to 34 weeks, after which the growth rate decreases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/11\">",
"     11",
"    </a>",
"    ]. The median growth rate in multiple gestations is lower than that of singletons during the third trimester (see topic reviews on twin and triplet pregnancy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Symmetric and asymmetric growth restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pattern of normal growth described above forms the basis for the clinical classification of FGR:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symmetric FGR, which comprises 20 to 30 percent of growth restricted fetuses, refers to a growth pattern in which all fetal organs are decreased proportionally due to global impairment of early fetal cellular hyperplasia.",
"     </li>",
"     <li>",
"      Asymmetric FGR is characterized by a relatively greater decrease in abdominal size (eg, liver volume and subcutaneous fat tissue) than head circumference and is found in the remaining 70 to 80 percent of the FGR population. Asymmetric fetal growth is thought to result from the capacity of the fetus to adapt to a hostile environment by redistributing blood flow in favor of vital organs (eg, brain, heart, placenta) at the expense of nonvital fetal organs (eg, abdominal viscera, lungs, skin, kidneys) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical assessment is a reasonable screening tool for FGR in low risk pregnancies, as there is no high quality evidence that alternative approaches, such as routine ultrasound examination, improve outcome over clinical assessment alone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Clinical assessment is based on assessment of past and present risk factors, physical examination, and ultrasound studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10616?source=see_link\">",
"     \"Overview of causes of and risk factors for fetal growth restriction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43576?source=see_link\">",
"     \"Routine prenatal ultrasonography as a screening tool\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Accurate assessment of gestational age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accurate knowledge of gestational age (GA) is critical to the diagnosis of FGR, given that normal and abnormal fetal size are defined, in part, by comparing the fetal weight of the index fetus to that of other fetuses of the same gestational age. A detailed discussion of determination of GA can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34553?source=see_link\">",
"     \"Prenatal assessment of gestational age\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a subgroup of fetuses, growth delay can be identified as early as the first trimester. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5783?source=see_link\">",
"     \"Diagnosis and outcome of first trimester growth delay\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Symphysis-fundal height measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of the distance between the upper edge of the pubic symphysis and the top of the uterine fundus using a tape measure is a simple, inexpensive, and widespread procedure performed during antenatal care to detect fetuses that are poorly grown. The first suspicion of FGR often arises when this length is noted to be discordant with the expected size for dates. Discordancy has been defined in various ways, the most common criteria is a fundal height in centimeters that is at least three centimeters below the GA in weeks (eg, fundal height 32 cm at 36 weeks of gestation) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The accuracy of fundal height measurements for screening for and diagnosis of FGR is controversial. A systematic review concluded there was not enough evidence (one trial) to evaluate the use of this technique versus abdominal palpation for detecting abnormal fetal growth [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/17\">",
"     17",
"    </a>",
"    ]. Observational studies using symphysis-fundal height measurements have reported a wide range of sensitivities: 17 to 86 percent of small fetuses were detected [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/16,18-22\">",
"     16,18-22",
"    </a>",
"    ]. The method performs best when all of the measurements are done by the same clinician using the unmarked side of the tape (to reduce bias [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/23\">",
"     23",
"    </a>",
"    ]) and are plotted to reflect fetal growth for the individual patient (&ldquo;customized&rdquo;), rather than against a standardized norm [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Other factors which may affect sensitivity include maternal size, bladder volume, parity, and ethnic group [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Abdominal palpation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical assessment of fetal size by abdominal palpation does not perform well as a test for detecting FGR: sensitivities range from 30 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/20,28,29\">",
"     20,28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SONOGRAPHIC SCREENING AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a general consensus that once the suspicion of FGR has arisen because of risk factors or physical examination, sonographic techniques should be used to try to confirm or exclude the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Clinical assessment alone is not adequate in pregnancies at high risk for FGR, given the low sensitivity and specificity. Risk factors that should prompt an ultrasound examination include significant lag of the fundal height on physical examination, suboptimal growth on a prior ultrasound, history of a prior birth of a small for gestational age infant, poor maternal weight gain, preeclampsia, or maternal conditions (eg, lupus erythematosus, hypertension) associated with suboptimal fetal growth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10616?source=see_link\">",
"     \"Overview of causes of and risk factors for fetal growth restriction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of sonographic parameters has been used to screen for and diagnose FGR. The procedures for measuring these parameters can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36824?source=see_link\">",
"     \"Ultrasound examination in obstetrics and gynecology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A major limitation in interpreting the predictive value of sonography for diagnosing FGR and comparing predictive values derived from different studies is that these values depend upon the prevalence of FGR in the population studied. Thus, ultrasound results need to be interpreted in terms of pretest risk of FGR and take into account whether the subject population was at low, moderate, or high risk of fetal growth abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/32-34\">",
"     32-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sonographic estimation of fetal weight is the single best morphometric test to screen for and diagnose FGR (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Estimated fetal weight (EFW)'",
"    </a>",
"    below). Customized and individualized growth curves may improve diagnostic performance (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Customized growth curves'",
"    </a>",
"    below). The other morphometric tests discussed below are more likely to overlook fetuses with symmetric FGR, but can be used as confirmatory tests of suspected asymmetric FGR. As discussed above, symmetric FGR comprises 20 to 30 percent of growth restricted fetuses and asymmetric FGR occurs in the remaining 70 to 80 percent of the FGR population.",
"   </p>",
"   <p>",
"    When ultrasound examination suggests a diagnosis of FGR, further evaluation to look for maternal, placental, or fetal disorders associated with impaired fetal growth is indicated. This evaluation helps to (1) distinguish the growth impaired fetus from the constitutionally small fetus, and (2) guide further management of the pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23994?source=see_link\">",
"     \"Fetal growth restriction: Evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Abdominal circumference",
"    </span>",
"    &nbsp;&mdash;&nbsp;When fetal growth is compromised, the fetal abdominal circumference (AC) is smaller than expected because of depletion of abdominal adipose tissue and decreased hepatic size related to reduced glycogen storage in the liver. Although the size of the fetal liver may be reduced as a result of fetal malnutrition, this is a less sensitive marker for FGR than AC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most studies report reduced AC is the most sensitive single morphometric indicator of FGR [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/37-42\">",
"     37-42",
"    </a>",
"    ]. The performance of AC measurement was illustrated by a study of 3616 pregnancies over 25 weeks of gestation that had a single ultrasound examination performed within two weeks of delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/41\">",
"     41",
"    </a>",
"    ]. AC measurement predicted small for gestational age (SGA) infants (ie, birth weight below the 10th percentile for GA) with sensitivity, specificity, positive and negative predictive values of 61, 95, 86, and 83 percent, respectively. Measurement of AC was more predictive of FGR than measurement of either head circumference (HC) or biparietal diameter (BPD) or the combination of AC with either one of these two variables. The optimal time to screen for FGR was at approximately 34 weeks of gestation.",
"   </p>",
"   <p>",
"    The following factors affect the sensitivity of the AC measurement:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symmetric versus asymmetric growth abnormality. AC is more sensitive in asymmetric FGR. As an example, a study of 151 SGA infants reported the sensitivity of AC was 73 percent in the asymmetrical group, 59 percent in the symmetrical group, and 64 percent for the entire population [",
"      <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gestational age. AC is more sensitive later in gestation. As an example, the sensitivity and positive predictive value of AC measurement at 29 to 31 weeks for prediction of FGR were 41 and 51 percent, respectively; however, these values increased at term to 88 and 71 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Time interval between AC measurements. AC is more sensitive when the interval between measurements is more than two weeks. This was illustrated by a study that showed that the false positive rates for inter-examination intervals of one, two, and four weeks were 31, 17, and 3 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Small AC also correlates with parameters of morbidity associated with FGR. Biochemical markers of hypoxia and acidemia are more common when the AC is below the 5th percentile for GA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Estimated fetal weight (EFW)",
"    </span>",
"    &nbsp;&mdash;&nbsp;AC alone can be used for predicting weight in normally growing fetuses at term and in low-risk populations; however, this method has limitations when used in preterm or growth restricted fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/31,46,47\">",
"     31,46,47",
"    </a>",
"    ]. Therefore, additional sonographic variables have been incorporated into models for predicting fetal growth abnormalities. Fetal weight estimation has become one of the most common methods of identifying the growth-restricted fetus since pediatricians use birth weight as their primary variable for defining growth restriction in the infant. Examples of fetal weight distribution by gestational age are provided in the tables; several such tables exist and are slightly different depending on the population studied (",
"    <a class=\"graphic graphic_table graphicRef56847 \" href=\"UTD.htm?16/54/17261\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75060 \" href=\"UTD.htm?2/30/2541\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9593?source=see_link\">",
"     \"Small for gestational age infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 1975, Campbell and Wilkin first published a regression equation for estimating fetal weight based upon sonographic measurement of the AC and HC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/48\">",
"     48",
"    </a>",
"    ]. Other equations have been published subsequently using two or more morphometric body measurements (eg, BPD, AC, HC, occipital frontal diameter, abdominal diameter, transthoracic circumference, and femur length [FL]) to improve sonographic accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/49-52\">",
"     49-52",
"    </a>",
"    ]. Equations that incorporate AC, BPD, and FL seem to provide the most accurate estimates of fetal weight [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/1/25?source=see_link\">",
"     \"Prenatal sonographic assessment of fetal weight\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, EFW assessments are within 10 percent of the actual birth weight in 75 percent of patients in whom there is a clinical suspicion of FGR [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/53\">",
"     53",
"    </a>",
"    ]. The average sensitivity, specificity, positive and negative predictive values for FGR using this parameter are approximately 90, 85, 80, and 90 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. EFW performed within two weeks of delivery is more predictive than when performed earlier in gestation.",
"   </p>",
"   <p>",
"    The sensitivity of EFW for predicting FGR and adverse outcome associated with FGR is generally higher for infants with severe growth restriction (birth weight &lt;3rd percentile). In one study, all infants with birth weight &lt;3",
"    <sup>",
"     rd",
"    </sup>",
"    percentile were identified prenatally [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/54\">",
"     54",
"    </a>",
"    ]. In another study including 1116 consecutive fetuses with EFW &lt;10",
"    <sup>",
"     th",
"    </sup>",
"    percentile, all 8 mortalities occurred among the 826 fetuses with EFW &lt;3",
"    <sup>",
"     rd",
"    </sup>",
"    percentile [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Customized growth curves",
"    </span>",
"    &nbsp;&mdash;&nbsp;EFW is typically classified using population-based birth weight centiles; however, multiple variables affect fetal weight and can be incorporated into individualized or customized centiles. These variables include fetal gender and maternal parity, ethnicity, height, weight, and age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]; maternal characteristics have greater fetal effects than paternal characteristics. A potentially better approach is to utilize large population-based data sets that account for these variables and exclude the effects of pathologic variables such as maternal smoking, hypertension, diabetes, and preterm birth. Using these data, the optimal birth weight and range of normal around this weight for a specific fetus can be estimated at term and can be determined for each gestational age to create an ultrasound-based, customized, optimal growth curve. The actual EFW is then plotted on this optimized customized curve to create the individual fetus' growth curve across gestation. Free software for calculating customized fetal weight centiles can be downloaded from the internet site",
"    <a class=\"external\" href=\"file://www.gestation.net/\">",
"     www.gestation.net",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Although no randomized trials are available [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/61\">",
"     61",
"    </a>",
"    ], several studies have compared the use of population-based birth weight centiles to customized centiles for prediction of SGA and perinatal morbidity. These studies have generally concluded that using a customized birth weight standard increases the identification of fetuses at risk of perinatal death and neonatal morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/62-69\">",
"     62-69",
"    </a>",
"    ], although the largest study found that neither the ultrasound-based nor the customized reference did well in predicting adverse perinatal outcomes, and was only useful at &le;5th centile [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/7\">",
"     7",
"    </a>",
"    ]. The small for gestational age fetus by population-based standards that is normal in size on this customized growth standard does not appear to be at risk of adverse outcome.",
"   </p>",
"   <p>",
"    This improvement in prediction of outcome may be related to better identification of the constitutionally small fetus through adjustment for maternal characteristics, or to use of an intrauterine (ultrasound) growth standard rather than a birth weight standard for classification of FGR. Since fetuses who are born preterm tend to have lower birth weights that fetuses of the same gestational age who remain in utero, using an intrauterine weight standard increases identification of FGR remote from term [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/70\">",
"     70",
"    </a>",
"    ]. The higher perinatal mortality among infants classified as FGR by the customized reference is largely due to the inclusion of more preterm births in this group [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/67,71,72\">",
"     67,71,72",
"    </a>",
"    ]. When adjusted for preterm birth, the use of customized fetal growth curves rather than population based growth curves does not clearly improve identification of pregnancies at increased risk of neonatal morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A long-term study suggested that none of the current standards predict long-term neurodevelopmental outcome well, although the customized standard performed slightly better than other standards [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Growth velocity",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, the use of any parameter (eg, AC, EFW) in the prediction of FGR is based upon accurate assessment of GA. If dates are unknown, serial sonographic examinations at two-week intervals should be performed to evaluate the rate of interval growth (ie, growth velocity). Irrespective of GA, there is a significantly lower rate of change over time of AC or EFW in FGR fetuses compared with those fetuses whose growth is appropriate for GA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/74\">",
"     74",
"    </a>",
"    ]. In one study, as an example, a change in fetal AC of less than 10 mm over a two-week period had a sensitivity of 85 percent and specificity of 74 percent for identifying FGR [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/75\">",
"     75",
"    </a>",
"    ]. Fetuses with normal growth velocity, amniotic fluid volume, and Doppler velocimetry are at low risk of complications associated with FGR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Body proportions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     HC/AC",
"    </span>",
"    ratio,",
"    <span class=\"nowrap\">",
"     FL/AC",
"    </span>",
"    ratio, and ponderal index have also been used to identify the growth restricted fetus, particularly in the setting of asymmetric FGR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     HC/AC ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     HC/AC",
"    </span>",
"    ratio has been proposed for evaluating fetuses with asymmetric FGR [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/76\">",
"     76",
"    </a>",
"    ]. In these infants, the size of the liver tends to be disproportionately small compared to the circumference of the head or length of the femur, which are initially spared from the effects of nutritional deficiency (see",
"    <a class=\"local\" href=\"#H27\">",
"     'Fetal cerebral arteries'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     HC/AC",
"    </span>",
"    ratio decreases linearly throughout pregnancy and a ratio greater than 2 standard deviations (SD) above the mean for GA is considered abnormal. One prospective study of the",
"    <span class=\"nowrap\">",
"     HC/AC",
"    </span>",
"    ratio for detecting asymmetric FGR due to uteroplacental insufficiency reported normal ratios in 79 percent of fetuses, none of whom were SGA; the remaining 21 percent had abnormal ratios and were diagnosed correctly as FGR [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/77\">",
"     77",
"    </a>",
"    ]. In contrast, the sensitivity, specificity, positive and negative predictive values of an abnormal",
"    <span class=\"nowrap\">",
"     HC/AC",
"    </span>",
"    in a population with FGR of mixed etiologies were 36, 90, 67, and 72 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings demonstrate that an abnormal",
"    <span class=\"nowrap\">",
"     HC/AC",
"    </span>",
"    ratio is more accurate in predicting FGR related to uteroplacental insufficiency (often asymmetric) than FGR from other etiologies (often symmetric). However, not all fetuses with an elevated",
"    <span class=\"nowrap\">",
"     HC/AC",
"    </span>",
"    ratio have FGR. As an example, macrocephaly could also be associated with an abnormal",
"    <span class=\"nowrap\">",
"     HC/AC,",
"    </span>",
"    which would be unrelated to FGR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     FL/AC ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     FL/AC",
"    </span>",
"    ratio uses sonographic elements that relate to both weight and length in the prediction of FGR. An",
"    <span class=\"nowrap\">",
"     FL/AC",
"    </span>",
"    ratio greater than 23.5 percent has a sensitivity of 56 to 64 percent and specificity of 74 to 90 percent for identification of asymmetric FGR [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. This ratio is independent of GA in normally grown fetuses in the last half of pregnancy. However, an abnormal",
"    <span class=\"nowrap\">",
"     FL/AC",
"    </span>",
"    ratio does not accurately diagnose symmetric FGR. The sensitivity, specificity, positive and negative predictive values of the 90th percentile of",
"    <span class=\"nowrap\">",
"     FL/AC",
"    </span>",
"    ratio in a mixed population of FGR fetuses were 30, 91,14, and 96 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therefore, the",
"    <span class=\"nowrap\">",
"     FL/AC",
"    </span>",
"    ratio is unsuitable for screening for FGR in the general population, but can be used as a GA independent parameter in high-risk pregnancies in which asymmetric FGR is suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Ponderal index",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatricians often use an abnormal ponderal index (ie, PI = [weight (in g) x 100] &divide; [length (in cm)](3)) to define growth restriction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/81\">",
"     81",
"    </a>",
"    ]. A fetal PI has been calculated based upon a sonographically derived EFW and measurement of the FL. One study reported sensitivity, specificity, and positive predictive value of the fetal PI for FGR of 77, 82, and 36 percent, respectively; however, there was a poor correlation between fetal and neonatal PI [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Transverse cerebellar diameter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth of the transverse cerebellar diameter (TCD) is not affected in FGR, thus TCD may serve as an independent indicator of GA against which other potential deviations of growth may be compared [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/83\">",
"     83",
"    </a>",
"    ]. The",
"    <span class=\"nowrap\">",
"     TCD/AC",
"    </span>",
"    ratio is constant (0.14+0.01; mean+SD) during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/84,85\">",
"     84,85",
"    </a>",
"    ], and a",
"    <span class=\"nowrap\">",
"     TCD/AC",
"    </span>",
"    ratio exceeding 2 SD above the mean is predictive of asymmetrical growth restriction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/85\">",
"     85",
"    </a>",
"    ]. A prospective study of the",
"    <span class=\"nowrap\">",
"     TCD/AC",
"    </span>",
"    ratio for identifying growth-restricted fetuses in pregnancies at risk reported sensitivity, specificity, positive and negative predictive values of 71, 77, 79, and 68 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/86\">",
"     86",
"    </a>",
"    ]. Fourteen FGR fetuses were missed by this ratio, eight of whom were severely growth restricted.",
"   </p>",
"   <p>",
"    The status of the",
"    <span class=\"nowrap\">",
"     TCD/AC",
"    </span>",
"    ratio as a predictor of FGR remains controversial due to limited data from large and controlled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/87,88\">",
"     87,88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Amniotic fluid volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oligohydramnios refers to amniotic fluid volume that is less than expected for gestational age. It is typically diagnosed by ultrasound examination and may be described qualitatively or quantitatively by various methods. These are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31558?source=see_link\">",
"     \"Assessment of amniotic fluid volume\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14233?source=see_link\">",
"     \"Oligohydramnios\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oligohydramnios is one of the sequelae of FGR. The proposed mechanism is diminished fetal urine production due to hypoxia-induced redistribution of blood flow to vital organs at the expense of less vital organs, such as the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. The presence of oligohydramnios has been evaluated as a diagnostic tool to predict both the presence of FGR and the level of associated fetal compromise.",
"   </p>",
"   <p>",
"    Oligohydramnios is difficult to assess accurately (as determined by dye-dilution studies) and commonly occurs with complications of pregnancy other than FGR. In addition, a significant proportion (approximately 15 to 80 percent) of fetuses with FGR do not have decreased amniotic fluid volume. Therefore, oligohydramnios is a poor screening modality for suboptimal growth [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/40,75,91,92\">",
"     40,75,91,92",
"    </a>",
"    ]. However, if it is present in the absence of ruptured membranes, congenital genitourinary anomalies, or prolonged pregnancy, FGR is the most likely etiology.",
"   </p>",
"   <p>",
"    Using the oligohydramnios definition of largest vertical fluid pocket less than 1 cm, Manning reported sensitivity, specificity, positive and negative predictive values for prediction of FGR of 84, 97, 90, and 95 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/93\">",
"     93",
"    </a>",
"    ]. However, other investigators have not confirmed these results. In one such study, this criterion was highly diagnostic of FGR, but had poor sensitivity (27 percent), and thus was inadequate as a screening test [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/92\">",
"     92",
"    </a>",
"    ]. Changing the definition of oligohydramnios to a vertical amniotic fluid pocket of less than 2 cm still resulted in poor sensitivity (16 percent), with specificity and positive predictive value of 98 and 78 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies using single and serial estimates of amniotic fluid volume by amniotic fluid index (AFI) in low risk pregnancies found that neither the rate of the change of AFI nor the final AFI measurement prior to delivery predicted any of the anthropometric criteria of FGR [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, pregnancies with the most severe oligohydramnios have the highest perinatal mortality rate, incidence of congenital anomalies (especially of the urinary tract), and incidence of FGR [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/94\">",
"     94",
"    </a>",
"    ]. Oligohydramnios is abnormal at any GA, therefore the observation of low amniotic fluid volume when GA is unknown suggests FGR is present (if rupture of membranes and urinary tract anomalies have been excluded) and that fetal biometric measurements may underestimate the true GA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Soft tissue measurements",
"    </span>",
"    &nbsp;&mdash;&nbsp;FGR results in a decrease in both adipose tissue and muscle mass. Measurement of fetal soft tissue is probably predictive of FGR; however, there are inadequate data for defining the best site for measurement or the sensitivity and specificity of this parameter.",
"   </p>",
"   <p>",
"    Measurement of the fetal thigh circumference incorporates the contributions of both adipose and muscle. In one study, a thigh circumference measuring 2 SD below the mean had a sensitivity of 78 percent and a positive predictive value of 85 percent in the prediction of FGR [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other measurements of fetal adipose tissue include subcutaneous tissue thickness at the level of the fetal midcalf, midthigh, or abdominal wall, and cheek-to-cheek diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. A prospective study of 137 unselected pregnancies, in which serial sonographic measurement of fetal subcutaneous abdominal fat were made, found that fetuses with subcutaneous fat of less than 5 mm at 38 weeks of gestation were approximately five-fold more likely to be SGA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/98\">",
"     98",
"    </a>",
"    ]. The sensitivity and specificity for diagnosis of FGR were 76 and 67 percent, respectively. In addition, the frequency of neonatal morbidity (eg, meconium aspiration, hypoglycemia, hypothermia, poor feeding, and jaundice) was significantly higher in infants with adipose tissue depletion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Doppler velocimetry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler ultrasound is a noninvasive technique commonly used to evaluate maternal and fetal hemodynamics. Continuous, adequate perfusion of the maternal and fetal sides of the placenta is necessary for normal fetal growth. FGR is associated with diminished flow and abnormal Doppler waveforms in both maternal and fetal vessels. Assessment of Doppler flow with appropriate intervention can reduce perinatal mortality in pregnancies complicated by FGR [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/99\">",
"     99",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10728?source=see_link\">",
"     \"Doppler ultrasound of the umbilical artery for fetal surveillance\"",
"    </a>",
"    .) Although useful for monitoring pregnancies complicated by FGR, Doppler of any vessel is not useful as a screening tool for identifying these pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Arteries, particularly the umbilical artery, are the vessels most commonly insonated. Venous Doppler assessment has been studied less extensively, and is used for monitoring, rather than diagnosis, of FGR. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14217?source=see_link\">",
"     \"Venous Doppler for fetal assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Uterine artery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine artery Doppler flow velocimetry has limited diagnostic accuracy for prediction of FGR and is not useful as a screening tool.",
"   </p>",
"   <p>",
"    Trophoblast invasion into the uterine vessels occurs in the first half of pregnancy and results in dilated spiral arteries, thereby creating a 10- to 12-fold increase in uterine perfusion, and providing nutrient supply and gas exchange for the fetus. The shape of the uterine artery velocity waveform is unique: it is characterized by high end-diastolic velocities with continuous forward blood flow throughout diastole. As GA advances, the degree of end-diastolic flow typically increases; however, failure of normal endovascular trophoblastic invasion of the spiral arteries results in increased uterine artery vascular resistance and decreased perfusion of the placenta [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. Preeclampsia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    FGR often subsequently develop [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     systolic/diastolic",
"    </span>",
"    <span class=\"nowrap\">",
"     (S/D)",
"    </span>",
"    ratio of the uterine artery in normal pregnancies should be less than 2.7 after the 26th week of gestation. If the end-diastolic flow does not increase throughout pregnancy or a small uterine artery notch is detected at the end of systole, the fetus is at high risk for developing FGR [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/104\">",
"     104",
"    </a>",
"    ]. Diastolic blood flow may be absent or even reversed with extreme degrees of placental dysfunction. Such findings are ominous and may precede fetal death or signal a high risk of abnormal fetal neurologic outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Doppler studies of the uterine artery in early pregnancy have been evaluated as a screening tool for pregnancies destined to develop preeclampsia or FGR. The predictive value of an abnormal test is low, although the association with these adverse outcomes is statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/106-108\">",
"     106-108",
"    </a>",
"    ]. As an example, a review of 27 uterine artery Doppler studies for the prediction of preeclampsia and associated complications (eg, FGR, perinatal death) included 12,994 pregnancies stratified into low or high risk for developing these problems [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/107\">",
"     107",
"    </a>",
"    ]. In low-risk women the pooled likelihood ratio for developing FGR was 3.6 (95% CI 3.2-4.0) for a positive test result and 0.8 (95% CI 0.8-0.9) for a negative test result. In the high-risk population, a positive test result predicted FGR with a pooled likelihood ratio of 2.7 (95% CI 2.1-3.4), whereas the likelihood ratio for a negative test was 0.7 (95% CI 0.6-0.9).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Umbilical artery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler umbilical artery studies are not useful for screening and diagnosis of FGR. Comparative studies are scarce, but support this conclusion. A prospective study examined whether Doppler velocimetry of the umbilical artery yielded better or earlier prediction of FGR than sonographic estimates of fetal weight [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/109\">",
"     109",
"    </a>",
"    ]. One hundred sixty-eight women at high risk for FGR were evaluated for growth restriction with Doppler and gray-scale ultrasound; 42 delivered an SGA infant. Sensitivity of the",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    ratio of the umbilical artery was lower than for sonographic estimates of fetal weight (55 versus 76 percent); however, the Doppler had higher specificity (92 versus 80 percent) and higher positive predictive value (73 versus 58 percent). The two techniques used together further improved the positive predictive value for diagnosis of FGR to 77 percent, with a negative predictive value of 93 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Doppler has been useful in evaluation and management of pregnancies suspected of FGR [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/111,112\">",
"     111,112",
"    </a>",
"    ]. Not all infants whose birth weight is below the 10th percentile have been exposed to a pathological process. Most small newborns are constitutionally small and healthy. Differentiating the fetus with pathological growth restriction who is at risk for perinatal complications from the constitutionally small, but healthy, fetus has been an ongoing challenge in obstetrics. This is the setting in which Doppler is useful because it can distinguish between these two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/57,113-115\">",
"     57,113-115",
"    </a>",
"    ] and guide timing of interventions (eg, intensive monitoring, antenatal glucocorticoids, early delivery) that reduce perinatal mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10728?source=see_link\">",
"     \"Doppler ultrasound of the umbilical artery for fetal surveillance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Fetal descending aorta",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other Doppler tests, the pulsatility index (ie, peak systolic minus minimal diastolic velocity divided by the mean velocity or",
"    <span class=\"nowrap\">",
"     S-D/mean)",
"    </span>",
"    of the fetal descending aorta is not useful for screening and diagnosis of FGR in the general obstetric population. It performs best for predicting the FGR fetus who is beginning to decompensate from chronic hypoxia and malnutrition.",
"   </p>",
"   <p>",
"    Normal blood flow in the fetal descending aorta is highly pulsatile, with a minimal end-diastolic component. This part of the aorta provides perfusion to the fetal abdominal organs, umbilical-placental circulation, and lower limbs. Increased placental impedance combined with redistribution of blood flow from nonvital to vital organs may result in changes in the aortic velocity waveforms. Assessment of these waveforms is limited to the pulsatility index because of the lack of diastolic flow.",
"   </p>",
"   <p>",
"    An elevated pulsatility index is associated with both FGR and adverse outcomes, such as severe FGR, necrotizing enterocolitis, nonreassuring fetal heart rate patterns, and perinatal mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/116-124\">",
"     116-124",
"    </a>",
"    ]. In one group of 30 fetuses with absent end-diastolic flow in the descending aorta, abnormal waveforms were detected at a mean of eight days prior to the onset of fetal heart rate (FHR) abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/120\">",
"     120",
"    </a>",
"    ]. All of the neonates were SGA and 66 percent had abnormal placentas with villous fibrosis and microfibrinous deposits.",
"   </p>",
"   <p>",
"    The sensitivity and specificity of absent end diastolic flow in the descending aorta for prediction of FGR with FHR abnormalities are approximately 85 and 80 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/122-124\">",
"     122-124",
"    </a>",
"    ]. These pregnancies are also characterized by higher rates of cesarean delivery, right ventricular failure, and perinatal mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Fetal renal artery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal renal artery Doppler is not a useful test in the initial diagnosis of FGR [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/90,125-127\">",
"     90,125-127",
"    </a>",
"    ]. It may be used to corroborate other tests or evaluate renal artery perfusion when oligohydramnios is observed. The pulsatility index of renal artery velocity waveforms in FGR is significantly elevated, possibly indicating decreased renal perfusion, which may, in turn, cause oligohydramnios. There is an overall negative correlation between the increase in pulsatility index and the amniotic fluid volume [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/127\">",
"     127",
"    </a>",
"    ]. In addition, umbilical blood sampling on FGR fetuses demonstrated a relationship between blood oxygen deficit and increased renal artery pulsatility index.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Fetal cerebral arteries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler evaluation of fetal cerebral arteries is not useful in the initial diagnosis of FGR, but may be useful confirming the diagnosis and evaluating the FGR fetus. In the normally developing fetus, the brain is an area of low vascular impedance and is the recipient of continuous forward flow throughout the cardiac cycle. Asymmetric FGR is likely caused by redistribution of fetal blood flow to the fetal brain, at the expense of less essential areas such as subcutaneous tissue, kidneys, and liver. However, the already low cerebral resistance has to drop even further to enhance cerebral blood flow. This has been measured as increased end diastolic velocities and decreased",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    ratios in the cerebral arteries of growth restricted fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/13,128-132\">",
"     13,128-132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study of blood flow in the internal carotid and umbilical arteries of 44 FGR fetuses reported the umbilical artery pulsatility index was increased by more than 2 SD in 80 percent of cases, whereas the internal carotid pulsatility index was reduced by more than 2 SD in only 45 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/129\">",
"     129",
"    </a>",
"    ]. This suggests that high placental impedance precedes the onset of the redistribution reflex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Venous Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venous Doppler has no role in diagnosis of FGR since venous Doppler abnormalities constitute a late circulatory finding. Venous Doppler assessment is used for monitoring fetal well-being; use of this technique appears to significantly improve the prediction of stillbirth and acidemia over use of umbilical artery Doppler alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14217?source=see_link\">",
"     \"Venous Doppler for fetal assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23994?source=see_link\">",
"     \"Fetal growth restriction: Evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Three-dimensional ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three-dimensional ultrasound has become available in the past decade and is being evaluated for assessment of pregnancies complicated by FGR [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/133-143\">",
"     133-143",
"    </a>",
"    ]. One study used this technique in 100 fetuses to compare birth weight predicted by calculating thigh volume to birth weight predicted by two-dimensional ultrasound using BPD, AC, and FL [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/139\">",
"     139",
"    </a>",
"    ]. All infants were delivered within 48 hours of ultrasound examination. The best-fit formula for thigh volume in the prediction of birth weight was linear and was superior to commonly used two-dimensional formulas. The error in birth weight prediction by three-dimensional ultrasound, Warsof's formula, Hadlock's formula, and Thurnau's formula were 0.7, 6.2, 6.7, and 20.8 percent respectively. In addition, three-dimensional ultrasound thigh volumetry was not influenced by oligohydramnios, fetal head engagement, or inaccurate abdominal circumference measurement. These results were confirmed in other studies that found three-dimensional thigh, femur, or humerus volume measurement was simple, and more accurate than two-dimensional ultrasound methods in the prediction of fetal weight [",
"    <a class=\"abstract\" href=\"UTD.htm?22/23/22906/abstract/140-143\">",
"     140-143",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three-dimensional ultrasound appears to be highly promising in the clinical setting of FGR because it appears to provide more precise information regarding structural abnormality, organ volumetry, EFW and oligohydramnios than standard two-dimensional techniques. However, this modality is not widely available and has not been adequately assessed in large or controlled studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnostic approach to fetal growth restriction (FGR) should integrate information from maternal history and physical examination with information from sonographic evaluation of the fetus, placenta, and amniotic fluid. The combined information helps to both confirm the diagnosis and establish the etiology for the growth abnormality. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ultrasound diagnosis of FGR is based on discrepancies between actual and expected biometric measurements for a given gestational age. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Sonographic screening and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no high quality evidence that ultrasound screening for FGR in low risk pregnancies improves pregnancy outcome over clinical assessment alone. We suggest screening for FGR by identifying the presence of risk factors and performing serial measurements of fundal height to identify discordancy between fundal height and gestational age (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Clinical suspicion of FGR should be followed with detailed sonographic assessment to make or exclude the diagnosis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A major limitation in interpreting the predictive value of sonography for diagnosing FGR and comparing predictive values derived from different studies is that these values depend upon the prevalence of FGR in the population studied. Thus, ultrasound results need to be interpreted in terms of pretest risk of FGR and take into account whether the subject population was at low, moderate, or high risk of fetal growth abnormality. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Sonographic screening and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The fetal AC is the most sensitive single morphometric measurement for diagnosis of FGR. However, it is not as predictive of FGR as sonographic estimation of fetal weight.",
"      <strong>",
"       Sonographic estimation of fetal weight is the best method for identifying fetuses whose birth weight is likely to be below the 10th percentile for gestational age",
"      </strong>",
"      . (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Abdominal circumference'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Estimated fetal weight (EFW)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abnormal",
"      <span class=\"nowrap\">",
"       HC/AC",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       FL/AC",
"      </span>",
"      ratios are particularly useful in the diagnosis of asymmetric fetal growth. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'HC/AC ratio'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'FL/AC ratio'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sonographic diagnosis of oligohydramnios corroborates the diagnosis of FGR by identifying one of the major consequences of the disorder. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Amniotic fluid volume'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The combination of an estimated fetal weight less than the 10th percentile for gestational age and abnormal umbilical artery Doppler velocimetry is highly predictive of FGR and is the best tool available for identifying the growth restricted fetus at risk of adverse outcome. These pregnancies require more intensive monitoring. Venous Doppler assessment is used for monitoring fetal well-being, but has no role in diagnosis of FGR since venous Doppler abnormalities constitute a late circulatory finding. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Doppler velocimetry'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is anticipated that three-dimensional volumetric fetal measurements will improve the accuracy of sonographic estimates of fetal weight, and thus our ability to identify the small fetus. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Three-dimensional ultrasonography'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/1\">",
"      McIntire DD, Bloom SL, Casey BM, Leveno KJ. Birth weight in relation to morbidity and mortality among newborn infants. N Engl J Med 1999; 340:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/2\">",
"      Pilliod RA, Cheng YW, Snowden JM, et al. The risk of intrauterine fetal death in the small-for-gestational-age fetus. Am J Obstet Gynecol 2012; 207:318.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/3\">",
"      Gardosi J, Madurasinghe V, Williams M, et al. Maternal and fetal risk factors for stillbirth: population based study. BMJ 2013; 346:f108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/4\">",
"      Lindqvist PG, Molin J. Does antenatal identification of small-for-gestational age fetuses significantly improve their outcome? Ultrasound Obstet Gynecol 2005; 25:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/5\">",
"      Battaglia FC, Lubchenco LO. A practical classification of newborn infants by weight and gestational age. J Pediatr 1967; 71:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/6\">",
"      Seeds JW, Peng T. Impaired growth and risk of fetal death: is the tenth percentile the appropriate standard? Am J Obstet Gynecol 1998; 178:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/7\">",
"      Zhang J, Mikolajczyk R, Grewal J, et al. Prenatal application of the individualized fetal growth reference. Am J Epidemiol 2011; 173:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/8\">",
"      Zhang J, Merialdi M, Platt LD, Kramer MS. Defining normal and abnormal fetal growth: promises and challenges. Am J Obstet Gynecol 2010; 202:522.",
"     </a>",
"    </li>",
"    <li>",
"     Manning, FA. Intrauterine growth retardation. In, Fetal Medicine. Principal and Practice. Norwalk, CT, Appleton &amp; Lange 1995 p. 317.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/10\">",
"      Minior VK, Shatzkin E, Divon MY. Nucleated red blood cell count in the differentiation of fetuses with pathologic growth restriction from healthy small-for-gestational-age fetuses. Am J Obstet Gynecol 2000; 182:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/11\">",
"      Resnik R. Intrauterine growth restriction. Obstet Gynecol 2002; 99:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/12\">",
"      Uerpairojkit B, Chan L, Reece AE, et al. Cerebellar Doppler velocimetry in the appropriate- and small-for-gestational-age fetus. Obstet Gynecol 1996; 87:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/13\">",
"      Bahado-Singh RO, Kovanci E, Jeffres A, et al. The Doppler cerebroplacental ratio and perinatal outcome in intrauterine growth restriction. Am J Obstet Gynecol 1999; 180:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/14\">",
"      Harkness UF, Mari G. Diagnosis and management of intrauterine growth restriction. Clin Perinatol 2004; 31:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/15\">",
"      Duff GB. A randomized controlled trial in a hospital population of ultrasound measurement screening for the small for dates baby. Aust N Z J Obstet Gynaecol 1993; 33:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/16\">",
"      Beliz&aacute;n JM, Villar J, Nardin JC, et al. Diagnosis of intrauterine growth retardation by a simple clinical method: measurement of uterine height. Am J Obstet Gynecol 1978; 131:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/17\">",
"      Robert Peter J, Ho JJ, Valliapan J, Sivasangari S. Symphysial fundal height (SFH) measurement in pregnancy for detecting abnormal fetal growth. Cochrane Database Syst Rev 2012; 7:CD008136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/18\">",
"      Rosenberg K, Grant JM, Tweedie I, et al. Measurement of fundal height as a screening test for fetal growth retardation. Br J Obstet Gynaecol 1982; 89:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/19\">",
"      Walraven GE, Mkanje RJ, van Roosmalen J, et al. Single pre-delivery symphysis-fundal height measurement as a predictor of birthweight and multiple pregnancy. Br J Obstet Gynaecol 1995; 102:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/20\">",
"      Rosenberg K, Grant JM, Hepburn M. Antenatal detection of growth retardation: actual practice in a large maternity hospital. Br J Obstet Gynaecol 1982; 89:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/21\">",
"      Persson B, Stangenberg M, Lunell NO, et al. Prediction of size of infants at birth by measurement of symphysis fundus height. Br J Obstet Gynaecol 1986; 93:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/22\">",
"      Lockwood CJ, Weiner S. Assessment of fetal growth. Clin Perinatol 1986; 13:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/23\">",
"      Jelks A, Cifuentes R, Ross MG. Clinician bias in fundal height measurement. Obstet Gynecol 2007; 110:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/24\">",
"      Bailey SM, Sarmandal P, Grant JM. A comparison of three methods of assessing inter-observer variation applied to measurement of the symphysis-fundal height. Br J Obstet Gynaecol 1989; 96:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/25\">",
"      Roex A, Nikpoor P, van Eerd E, et al. Serial plotting on customised fundal height charts results in doubling of the antenatal detection of small for gestational age fetuses in nulliparous women. Aust N Z J Obstet Gynaecol 2012; 52:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/26\">",
"      Mongelli M, Gardosi J. Symphysis-fundus height and pregnancy characteristics in ultrasound-dated pregnancies. Obstet Gynecol 1999; 94:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/27\">",
"      Engstrom JL, Ostrenga KG, Plass RV, Work BA. The effect of maternal bladder volume on fundal height measurements. Br J Obstet Gynaecol 1989; 96:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/28\">",
"      Hall MH, Chng PK, MacGillivray I. Is routine antenatal care worth while? Lancet 1980; 2:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/29\">",
"      Bais JM, Eskes M, Pel M, et al. Effectiveness of detection of intrauterine growth retardation by abdominal palpation as screening test in a low risk population: an observational study. Eur J Obstet Gynecol Reprod Biol 2004; 116:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/30\">",
"      Harding K, Evans S, Newnham J. Screening for the small fetus: a study of the relative efficacies of ultrasound biometry and symphysiofundal height. Aust N Z J Obstet Gynaecol 1995; 35:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/31\">",
"      Duncan KR, Issa B, Moore R, et al. A comparison of fetal organ measurements by echo-planar magnetic resonance imaging and ultrasound. BJOG 2005; 112:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/32\">",
"      Simon NV, O'Connor TJ 3rd, Shearer DM. Detection of intrauterine fetal growth retardation with abdominal circumference and estimated fetal weight using cross-sectional growth curves. J Clin Ultrasound 1990; 18:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/33\">",
"      Hill LM, Guzick D, Belfar HL, et al. A combined historic and sonographic score for the detection of intrauterine growth retardation. Obstet Gynecol 1989; 73:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/34\">",
"      Benson CB, Belville JS, Lentini JF, et al. Intrauterine growth retardation: diagnosis based on multiple parameters--a prospective study. Radiology 1990; 177:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/35\">",
"      Roberts AB, Mitchell JM, McCowan LM, Barker S. Ultrasonographic measurement of liver length in the small-for-gestational-age fetus. Am J Obstet Gynecol 1999; 180:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/36\">",
"      Senoh D, Hata T, Kitao M. Fetal liver length measurement does not provide a superior means for prediction of a small for gestational age fetus. Am J Perinatol 1994; 11:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/37\">",
"      Snijders RJ, Nicolaides KH. Fetal biometry at 14-40 weeks' gestation. Ultrasound Obstet Gynecol 1994; 4:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/38\">",
"      Brown HL, Miller JM Jr, Gabert HA, Kissling G. Ultrasonic recognition of the small-for-gestational-age fetus. Obstet Gynecol 1987; 69:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/39\">",
"      Chang TC, Robson SC, Boys RJ, Spencer JA. Prediction of the small for gestational age infant: which ultrasonic measurement is best? Obstet Gynecol 1992; 80:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/40\">",
"      Owen P, Khan KS, Howie P. Single and serial estimates of amniotic fluid volume and umbilical artery resistance in the prediction of intrauterine growth restriction. Ultrasound Obstet Gynecol 1999; 13:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/41\">",
"      Warsof SL, Cooper DJ, Little D, Campbell S. Routine ultrasound screening for antenatal detection of intrauterine growth retardation. Obstet Gynecol 1986; 67:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/42\">",
"      Chambers SE, Hoskins PR, Haddad NG, et al. A comparison of fetal abdominal circumference measurements and Doppler ultrasound in the prediction of small-for-dates babies and fetal compromise. Br J Obstet Gynaecol 1989; 96:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/43\">",
"      Ferrazzi E, Nicolini U, Kustermann A, Pardi G. Routine obstetric ultrasound: effectiveness of cross-sectional screening for fetal growth retardation. J Clin Ultrasound 1986; 14:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/44\">",
"      Mongelli M, Ek S, Tambyrajia R. Screening for fetal growth restriction: a mathematical model of the effect of time interval and ultrasound error. Obstet Gynecol 1998; 92:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/45\">",
"      Hecher K, Snijders R, Campbell S, Nicolaides K. Fetal venous, intracardiac, and arterial blood flow measurements in intrauterine growth retardation: relationship with fetal blood gases. Am J Obstet Gynecol 1995; 173:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/46\">",
"      Hadlock FP. Sonographic estimation of fetal age and weight. Radiol Clin North Am 1990; 28:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/47\">",
"      David C, Tagliavini G, Pilu G, et al. Receiver-operator characteristic curves for the ultrasonographic prediction of small-for-gestational-age fetuses in low-risk pregnancies. Am J Obstet Gynecol 1996; 174:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/48\">",
"      Campbell S, Wilkin D. Ultrasonic measurement of fetal abdomen circumference in the estimation of fetal weight. Br J Obstet Gynaecol 1975; 82:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/49\">",
"      Shepard MJ, Richards VA, Berkowitz RL, et al. An evaluation of two equations for predicting fetal weight by ultrasound. Am J Obstet Gynecol 1982; 142:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/50\">",
"      Ott WJ, Doyle S, Flamm S, Wittman J. Accurate ultrasonic estimation of fetal weight. Prospective analysis of new ultrasonic formulas. Am J Perinatol 1986; 3:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/51\">",
"      Vintzileos AM, Campbell WA, Rodis JF, et al. Fetal weight estimation formulas with head, abdominal, femur, and thigh circumference measurements. Am J Obstet Gynecol 1987; 157:410.",
"     </a>",
"    </li>",
"    <li>",
"     Hadlock FP: Evaluation of fetal weight estimation procedures. In: Quantitative Obstetrical Ultrasonography, Deter, RL (Ed), Wiley Medical, New York, 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/53\">",
"      Guidetti DA, Divon MY, Braverman JJ, et al. Sonographic estimates of fetal weight in the intrauterine growth retardation population. Am J Perinatol 1990; 7:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/54\">",
"      Ott WJ, Doyle S. Ultrasonic diagnosis of altered fetal growth by use of a normal ultrasonic fetal weight curve. Obstet Gynecol 1984; 63:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/55\">",
"      Divon MY, Guidetti DA, Braverman JJ, et al. Intrauterine growth retardation--a prospective study of the diagnostic value of real-time sonography combined with umbilical artery flow velocimetry. Obstet Gynecol 1988; 72:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/56\">",
"      Palo P, Erkkola R, Piiroinen O, Ruotsalainen P. Accuracy of ultrasonic fetal weight estimation and detection of small for gestational age fetuses. Am J Perinatol 1989; 6:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/57\">",
"      Baschat AA, Weiner CP. Umbilical artery doppler screening for detection of the small fetus in need of antepartum surveillance. Am J Obstet Gynecol 2000; 182:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/58\">",
"      Unterscheider J, Daly S, Geary MP, et al. Optimizing the definition of intrauterine growth restriction: the multicenter prospective PORTO Study. Am J Obstet Gynecol 2013; 208:290.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/59\">",
"      Gardosi J, Mongelli M, Wilcox M, Chang A. An adjustable fetal weight standard. Ultrasound Obstet Gynecol 1995; 6:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/60\">",
"      Gardosi J, Francis A. A customized standard to assess fetal growth in a US population. Am J Obstet Gynecol 2009; 201:25.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/61\">",
"      Carberry AE, Gordon A, Bond DM, et al. Customised versus population-based growth charts as a screening tool for detecting small for gestational age infants in low-risk pregnant women. Cochrane Database Syst Rev 2011; :CD008549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/62\">",
"      Clausson B, Gardosi J, Francis A, Cnattingius S. Perinatal outcome in SGA births defined by customised versus population-based birthweight standards. BJOG 2001; 108:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/63\">",
"      de Jong CL, Gardosi J, Dekker GA, et al. Application of a customised birthweight standard in the assessment of perinatal outcome in a high risk population. Br J Obstet Gynaecol 1998; 105:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/64\">",
"      McCowan LM, Harding JE, Stewart AW. Customized birthweight centiles predict SGA pregnancies with perinatal morbidity. BJOG 2005; 112:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/65\">",
"      De Jong CL, Francis A, Van Geijn HP, Gardosi J. Customized fetal weight limits for antenatal detection of fetal growth restriction. Ultrasound Obstet Gynecol 2000; 15:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/66\">",
"      Sciscione AC, Gorman R, Callan NA. Adjustment of birth weight standards for maternal and infant characteristics improves the prediction of outcome in the small-for-gestational-age infant. Am J Obstet Gynecol 1996; 175:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/67\">",
"      Groom KM, Poppe KK, North RA, McCowan LM. Small-for-gestational-age infants classified by customized or population birthweight centiles: impact of gestational age at delivery. Am J Obstet Gynecol 2007; 197:239.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/68\">",
"      Gardosi J, Francis A. Adverse pregnancy outcome and association with small for gestational age birthweight by customized and population-based percentiles. Am J Obstet Gynecol 2009; 201:28.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/69\">",
"      Ego A, Subtil D, Grange G, et al. Customized versus population-based birth weight standards for identifying growth restricted infants: a French multicenter study. Am J Obstet Gynecol 2006; 194:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/70\">",
"      Hutcheon JA, Zhang X, Cnattingius S, et al. Customised birthweight percentiles: does adjusting for maternal characteristics matter? BJOG 2008; 115:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/71\">",
"      Zhang X, Platt RW, Cnattingius S, et al. The use of customised versus population-based birthweight standards in predicting perinatal mortality. BJOG 2007; 114:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/72\">",
"      Larkin JC, Hill LM, Speer PD, Simhan HN. Risk of morbid perinatal outcomes in small-for-gestational-age pregnancies: customized compared with conventional standards of fetal growth. Obstet Gynecol 2012; 119:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/73\">",
"      Neta G, Grewal J, Mikolajczyk R, et al. Does the individualized reference outperform a simple ultrasound-based reference applied to birth weight in predicting child neurodevelopment? Ultrasound Obstet Gynecol 2011; 38:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/74\">",
"      de Jong CL, Francis A, van Geijn HP, Gardosi J. Fetal growth rate and adverse perinatal events. Ultrasound Obstet Gynecol 1999; 13:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/75\">",
"      Divon MY, Chamberlain PF, Sipos L, et al. Identification of the small for gestational age fetus with the use of gestational age-independent indices of fetal growth. Am J Obstet Gynecol 1986; 155:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/76\">",
"      Campbell S, Thoms A. Ultrasound measurement of the fetal head to abdomen circumference ratio in the assessment of growth retardation. Br J Obstet Gynaecol 1977; 84:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/77\">",
"      Crane JP, Kopta MM. Prediction of intrauterine growth retardation via ultrasonically measured head/abdominal circumference ratios. Obstet Gynecol 1979; 54:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/78\">",
"      Hadlock FP, Deter RL, Harrist RB, et al. A date-independent predictor of intrauterine growth retardation: femur length/abdominal circumference ratio. AJR Am J Roentgenol 1983; 141:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/79\">",
"      Benson CB, Doubilet PM, Saltzman DH, Jones TB. FL/AC ratio: poor predictor of intrauterine growth retardation. Invest Radiol 1985; 20:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/80\">",
"      Shalev E, Romano S, Weiner E, Ben-Ami M. Predictive value of the femur length to abdominal circumference ratio in the diagnosis of intrauterine growth retardation. Isr J Med Sci 1991; 27:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/81\">",
"      Weiner CP, Robinson D. Sonographic diagnosis of intrauterine growth retardation using the postnatal ponderal index and the crown-heel length as standards of diagnosis. Am J Perinatol 1989; 6:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/82\">",
"      Vintzileos AM, Lodeiro JG, Feinstein SJ, et al. Value of fetal ponderal index in predicting growth retardation. Obstet Gynecol 1986; 67:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/83\">",
"      Reece EA, Goldstein I, Pilu G, Hobbins JC. Fetal cerebellar growth unaffected by intrauterine growth retardation: a new parameter for prenatal diagnosis. Am J Obstet Gynecol 1987; 157:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/84\">",
"      Campbell WA, Nardi D, Vintzileos AM, et al. Transverse cerebellar diameter/abdominal circumference ratio throughout pregnancy: a gestational age-independent method to assess fetal growth. Obstet Gynecol 1991; 77:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/85\">",
"      Dilmen G, Toppare MF, Turhan NO, et al. Transverse cerebellar diameter and transverse cerebellar diameter/ abdominal circumference index for assessing fetal growth. Fetal Diagn Ther 1996; 11:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/86\">",
"      Campbell WA, Vintzileos AM, Rodis JF, et al. Use of the transverse cerebellar diameter/abdominal circumference ratio in pregnancies at risk for intrauterine growth retardation. J Clin Ultrasound 1994; 22:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/87\">",
"      Meyer WJ, Gauthier D, Ramakrishnan V, Sipos J. Ultrasonographic detection of abnormal fetal growth with the gestational age-independent, transverse cerebellar diameter/abdominal circumference ratio. Am J Obstet Gynecol 1994; 171:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/88\">",
"      Hill LM, Guzick D, DiNofrio D, et al. Ratios between the abdominal circumference, head circumference, or femur length and the transverse cerebellar diameter of the growth-retarded and macrosomic fetus. Am J Perinatol 1994; 11:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/89\">",
"      Nicolaides KH, Peters MT, Vyas S, et al. Relation of rate of urine production to oxygen tension in small-for-gestational-age fetuses. Am J Obstet Gynecol 1990; 162:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/90\">",
"      Veille JC, Kanaan C. Duplex Doppler ultrasonographic evaluation of the fetal renal artery in normal and abnormal fetuses. Am J Obstet Gynecol 1989; 161:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/91\">",
"      Chauhan SP, Magann EF, Dohrety DA, et al. Prediction of small for gestational age newborns using ultrasound estimated and actual amniotic fluid volume: published data revisited. Aust N Z J Obstet Gynaecol 2008; 48:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/92\">",
"      Patterson RM, Prihoda TJ, Pouliot MR. Sonographic amniotic fluid measurement and fetal growth retardation: a reappraisal. Am J Obstet Gynecol 1987; 157:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/93\">",
"      Manning FA, Hill LM, Platt LD. Qualitative amniotic fluid volume determination by ultrasound: antepartum detection of intrauterine growth retardation. Am J Obstet Gynecol 1981; 139:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/94\">",
"      Chamberlain PF, Manning FA, Morrison I, et al. Ultrasound evaluation of amniotic fluid volume. I. The relationship of marginal and decreased amniotic fluid volumes to perinatal outcome. Am J Obstet Gynecol 1984; 150:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/95\">",
"      Hill LM, Guzick D, Thomas ML, et al. Thigh circumference in the detection of intrauterine growth retardation. Am J Perinatol 1989; 6:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/96\">",
"      Abramowicz JS, Sherer DM, Bar-Tov E, Woods JR Jr. The cheek-to-cheek diameter in the ultrasonographic assessment of fetal growth. Am J Obstet Gynecol 1991; 165:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/97\">",
"      Hill LM, Guzick D, Boyles D, et al. Subcutaneous tissue thickness cannot be used to distinguish abnormalities of fetal growth. Obstet Gynecol 1992; 80:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/98\">",
"      Gardeil F, Greene R, Stuart B, Turner MJ. Subcutaneous fat in the fetal abdomen as a predictor of growth restriction. Obstet Gynecol 1999; 94:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/99\">",
"      Todros T, Sciarrone A, Piccoli E, et al. Umbilical Doppler waveforms and placental villous angiogenesis in pregnancies complicated by fetal growth restriction. Obstet Gynecol 1999; 93:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/100\">",
"      Society for Maternal-Fetal Medicine Publications Committee, Berkley E, Chauhan SP, Abuhamad A. Doppler assessment of the fetus with intrauterine growth restriction. Am J Obstet Gynecol 2012; 206:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/101\">",
"      Khong TY, De Wolf F, Robertson WB, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 1986; 93:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/102\">",
"      Lin S, Shimizu I, Suehara N, et al. Uterine artery Doppler velocimetry in relation to trophoblast migration into the myometrium of the placental bed. Obstet Gynecol 1995; 85:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/103\">",
"      Matijevic R, Johnston T. In vivo assessment of failed trophoblastic invasion of the spiral arteries in pre-eclampsia. Br J Obstet Gynaecol 1999; 106:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/104\">",
"      Schulman H, Fleischer A, Farmakides G, et al. Development of uterine artery compliance in pregnancy as detected by Doppler ultrasound. Am J Obstet Gynecol 1986; 155:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/105\">",
"      Valcamonico A, Danti L, Frusca T, et al. Absent end-diastolic velocity in umbilical artery: risk of neonatal morbidity and brain damage. Am J Obstet Gynecol 1994; 170:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/106\">",
"      Papageorghiou AT, Yu CK, Nicolaides KH. The role of uterine artery Doppler in predicting adverse pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 2004; 18:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/107\">",
"      Chien PF, Arnott N, Gordon A, et al. How useful is uterine artery Doppler flow velocimetry in the prediction of pre-eclampsia, intrauterine growth retardation and perinatal death? An overview. BJOG 2000; 107:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/108\">",
"      Dugoff L, Lynch AM, Cioffi-Ragan D, et al. First trimester uterine artery Doppler abnormalities predict subsequent intrauterine growth restriction. Am J Obstet Gynecol 2005; 193:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/109\">",
"      Berkowitz GS, Chitkara U, Rosenberg J, et al. Sonographic estimation of fetal weight and Doppler analysis of umbilical artery velocimetry in the prediction of intrauterine growth retardation: a prospective study. Am J Obstet Gynecol 1988; 158:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/110\">",
"      Ott WJ. Comparison of dynamic image and pulsed Doppler ultrasonography for the diagnosis of intrauterine growth retardation. J Clin Ultrasound 1990; 18:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/111\">",
"      Baschat AA. Pathophysiology of fetal growth restriction: implications for diagnosis and surveillance. Obstet Gynecol Surv 2004; 59:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/112\">",
"      Morris RK, Malin G, Robson SC, et al. Fetal umbilical artery Doppler to predict compromise of fetal/neonatal wellbeing in a high-risk population: systematic review and bivariate meta-analysis. Ultrasound Obstet Gynecol 2011; 37:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/113\">",
"      Burke G, Stuart B, Crowley P, et al. Is intrauterine growth retardation with normal umbilical artery blood flow a benign condition? BMJ 1990; 300:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/114\">",
"      Pattinson RC, Norman K, Odendaal HJ. The role of Doppler velocimetry in the management of high risk pregnancies. Br J Obstet Gynaecol 1994; 101:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/115\">",
"      McCowan LM, Harding JE, Stewart AW. Umbilical artery Doppler studies in small for gestational age babies reflect disease severity. BJOG 2000; 107:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/116\">",
"      Soothill PW, Nicolaides KH, Bilardo CM, Campbell S. Relation of fetal hypoxia in growth retardation to mean blood velocity in the fetal aorta. Lancet 1986; 2:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/117\">",
"      Jouppila P, Kirkinen P. Blood velocity waveforms of the fetal aorta in normal and hypertensive pregnancies. Obstet Gynecol 1986; 67:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/118\">",
"      Laurin J, Lingman G, Mars&aacute;l K, Persson PH. Fetal blood flow in pregnancies complicated by intrauterine growth retardation. Obstet Gynecol 1987; 69:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/119\">",
"      Hackett GA, Campbell S, Gamsu H, et al. Doppler studies in the growth retarded fetus and prediction of neonatal necrotising enterocolitis, haemorrhage, and neonatal morbidity. Br Med J (Clin Res Ed) 1987; 294:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/120\">",
"      Arabin B, Siebert M, Jimenez E, Saling E. Obstetrical characteristics of a loss of end-diastolic velocities in the fetal aorta and/or umbilical artery using Doppler ultrasound. Gynecol Obstet Invest 1988; 25:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/121\">",
"      Tonge HM, Wladimiroff JW, Noordam MJ, van Kooten C. Blood flow velocity waveforms in the descending fetal aorta: comparison between normal and growth-retarded pregnancies. Obstet Gynecol 1986; 67:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/122\">",
"      Bonatz G, Schulz V, Weisner D, Jonat W. Fetal heart rate (FHR) pathology in labor related to preceeding Doppler sonographic results of the umbilical artery and fetal aorta in appropriate and small for gestational age babies. A longitudinal analysis. J Perinat Med 1997; 25:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/123\">",
"      Mars&aacute;l K, Laurin J, Lindblad A, Lingman G. Blood flow in the fetal descending aorta. Semin Perinatol 1987; 11:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/124\">",
"      Jouppila P, Kirkinen P. Noninvasive assessment of fetal aortic blood flow in normal and abnormal pregnancies. Clin Obstet Gynecol 1989; 32:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/125\">",
"      Vyas S, Nicolaides KH, Campbell S. Renal artery flow-velocity waveforms in normal and hypoxemic fetuses. Am J Obstet Gynecol 1989; 161:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/126\">",
"      Arduini D, Rizzo G. Fetal renal artery velocity waveforms and amniotic fluid volume in growth-retarded and post-term fetuses. Obstet Gynecol 1991; 77:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/127\">",
"      Yoshimura S, Masuzaki H, Gotoh H, Ishimaru T. Fetal redistribution of blood flow and amniotic fluid volume in growth-retarded fetuses. Early Hum Dev 1997; 47:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/128\">",
"      Arabin B, Bergmann PL, Saling E. Simultaneous assessment of blood flow velocity waveforms in uteroplacental vessels, the umbilical artery, the fetal aorta and the fetal common carotid artery. Fetal Ther 1987; 2:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/129\">",
"      Wladimiroff JW, Noordam MJ, van den Wijngaard JA, Hop WC. Fetal internal carotid and umbilical artery blood flow velocity waveforms as a measure of fetal well-being in intrauterine growth retardation. Pediatr Res 1988; 24:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/130\">",
"      Strigini FA, De Luca G, Lencioni G, et al. Middle cerebral artery velocimetry: different clinical relevance depending on umbilical velocimetry. Obstet Gynecol 1997; 90:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/131\">",
"      Fong KW, Ohlsson A, Hannah ME, et al. Prediction of perinatal outcome in fetuses suspected to have intrauterine growth restriction: Doppler US study of fetal cerebral, renal, and umbilical arteries. Radiology 1999; 213:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/132\">",
"      Gramellini D, Folli MC, Raboni S, et al. Cerebral-umbilical Doppler ratio as a predictor of adverse perinatal outcome. Obstet Gynecol 1992; 79:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/133\">",
"      Ploeckinger-Ulm B, Ulm MR, Lee A, et al. Antenatal depiction of fetal digits with three-dimensional ultrasonography. Am J Obstet Gynecol 1996; 175:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/134\">",
"      Mueller GM, Weiner CP, Yankowitz J. Three-dimensional ultrasound in the evaluation of fetal head and spine anomalies. Obstet Gynecol 1996; 88:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/135\">",
"      Schild RL, Wallny T, Fimmers R, Hansmann M. Fetal lumbar spine volumetry by three-dimensional ultrasound. Ultrasound Obstet Gynecol 1999; 13:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/136\">",
"      Lee A, Kratochwil A, St&uuml;mpflen I, et al. Fetal lung volume determination by three-dimensional ultrasonography. Am J Obstet Gynecol 1996; 175:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/137\">",
"      Chang FM, Hsu KF, Ko HC, et al. Three-dimensional ultrasound assessment of fetal liver volume in normal pregnancy: a comparison of reproducibility with two-dimensional ultrasound and a search for a volume constant. Ultrasound Med Biol 1997; 23:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/138\">",
"      Liang RI, Chang FM, Yao BL, et al. Predicting birth weight by fetal upper-arm volume with use of three-dimensional ultrasonography. Am J Obstet Gynecol 1997; 177:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/139\">",
"      Chang FM, Liang RI, Ko HC, et al. Three-dimensional ultrasound-assessed fetal thigh volumetry in predicting birth weight. Obstet Gynecol 1997; 90:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/140\">",
"      Song TB, Moore TR, Lee JI, et al. Fetal weight prediction by thigh volume measurement with three-dimensional ultrasonography. Obstet Gynecol 2000; 96:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/141\">",
"      Chang CH, Tsai PY, Yu CH, et al. Prenatal detection of fetal growth restriction by fetal femur volume: efficacy assessment using three-dimensional ultrasound. Ultrasound Med Biol 2007; 33:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/142\">",
"      Chang CH, Yu CH, Ko HC, et al. Predicting fetal growth restriction by humerus volume: A three-dimensional ultrasound study. Ultrasound Med Biol 2006; 32:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/23/22906/abstract/143\">",
"      Chang CH, Yu CH, Ko HC, et al. The efficacy assessment of thigh volume in predicting intrauterine fetal growth restriction by three-dimensional ultrasound. Ultrasound Med Biol 2005; 31:883.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6752 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-543E46505B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_23_22906=[""].join("\n");
var outline_f22_23_22906=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NORMAL AND ABNORMAL FETAL GROWTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Normal growth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Symmetric and asymmetric growth restriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Accurate assessment of gestational age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Symphysis-fundal height measurement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Abdominal palpation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SONOGRAPHIC SCREENING AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Abdominal circumference",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Estimated fetal weight (EFW)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Customized growth curves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Growth velocity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Body proportions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - HC/AC ratio",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - FL/AC ratio",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Ponderal index",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Transverse cerebellar diameter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Amniotic fluid volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Soft tissue measurements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Doppler velocimetry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Uterine artery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Umbilical artery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Fetal descending aorta",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Fetal renal artery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Fetal cerebral arteries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Venous Doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Three-dimensional ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6752\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6752|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/30/2541\" title=\"table 1\">",
"      10th percentile by gestational age and sex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/54/17261\" title=\"table 2\">",
"      Birth weight percentiles by gestational age",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31558?source=related_link\">",
"      Assessment of amniotic fluid volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5783?source=related_link\">",
"      Diagnosis and outcome of first trimester growth delay",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10728?source=related_link\">",
"      Doppler ultrasound of the umbilical artery for fetal surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23994?source=related_link\">",
"      Fetal growth restriction: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14233?source=related_link\">",
"      Oligohydramnios",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10616?source=related_link\">",
"      Overview of causes of and risk factors for fetal growth restriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39477?source=related_link\">",
"      Possible role of low birth weight in the pathogenesis of essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34553?source=related_link\">",
"      Prenatal assessment of gestational age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/1/25?source=related_link\">",
"      Prenatal sonographic assessment of fetal weight",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43576?source=related_link\">",
"      Routine prenatal ultrasonography as a screening tool",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9593?source=related_link\">",
"      Small for gestational age infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36824?source=related_link\">",
"      Ultrasound examination in obstetrics and gynecology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14217?source=related_link\">",
"      Venous Doppler for fetal assessment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_23_22907="INTERMACS levels of limitation at the time of implant";
var content_f22_23_22907=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F83827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F83827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Interagency registry for mechanically assisted circulatory support (INTERMACS) levels of limitation at the time of implant",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        INTERMACS profile level",
"       </td>",
"       <td class=\"subtitle1\">",
"        Status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Level 1",
"       </td>",
"       <td>",
"        Critical cardiogenic shock",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Level 2",
"       </td>",
"       <td>",
"        Progressive decline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Level 3",
"       </td>",
"       <td>",
"        Stable but inotrope dependent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Level 4",
"       </td>",
"       <td>",
"        Recurrent advanced heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Level 5",
"       </td>",
"       <td>",
"        Exertion intolerant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Level 6",
"       </td>",
"       <td>",
"        Exertion limited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Level 7",
"       </td>",
"       <td>",
"        Advanced NYHA Class III",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Stevenson LW, Pagani FD, Young JB, et al. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant 2009; 28:535. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_23_22907=[""].join("\n");
var outline_f22_23_22907=null;
var title_f22_23_22908="Zoonoses from dogs B";
var content_f22_23_22908=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Zoonoses dogs, continued",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Transmission",
"       </td>",
"       <td class=\"subtitle1\">",
"        Organism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Human symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Canine symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Geographic distribution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"8\">",
"        Insect bites",
"       </td>",
"       <td>",
"        B. burgdorferi",
"       </td>",
"       <td>",
"        Erythema migrans, Lyme disease (multisystem inflammatory disease)",
"       </td>",
"       <td>",
"        Sudden onset lameness, swollen joints",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rickettsia rickettsii",
"       </td>",
"       <td>",
"        Rocky Mountain spotted fever, Fever, headache, followed by rash",
"       </td>",
"       <td>",
"        Similar to human disease",
"       </td>",
"       <td>",
"        North America",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ehrlichia chaffeensis and Anaplasma phagocytophilum",
"       </td>",
"       <td>",
"        Ehrlichiosis, Fever with variable symptoms (malaise, myalgias, headache)",
"       </td>",
"       <td>",
"        Similar to human disease",
"       </td>",
"       <td>",
"        Focal areas of United States",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Babesia microti or B. divergens",
"       </td>",
"       <td>",
"        Babesiosis, Asymptomatic to severe hemolytic anemia",
"       </td>",
"       <td>",
"        Similar to human disease",
"       </td>",
"       <td>",
"        Babesia microti (United States, primarily Northeast); Babesia divergens (Europe)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Francisella tularensis",
"       </td>",
"       <td>",
"        Tularemia, Abrupt onset fever, chills, HA, single erythematous papuloulcerative lesion with eschar",
"       </td>",
"       <td>",
"        Fever, loss of appetite",
"       </td>",
"       <td>",
"        Majority in south central United States",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yersinia pestis",
"       </td>",
"       <td>",
"        Plague, Abrupt onset fever, chills, HA Acute bubo",
"       </td>",
"       <td>",
"        Self-limited illness",
"       </td>",
"       <td>",
"        Worldwide except Australia; in United States, mostly Southwestern states",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dirofilaria immitis",
"       </td>",
"       <td>",
"        Urticarial skin eruption; \"coin lesion\" in lung",
"       </td>",
"       <td>",
"        Heartworm Most asymptomatic Exercise intolerance Hemoptysis",
"       </td>",
"       <td>",
"        Worldwide; particularly common in the Mediterranean",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leishmania",
"       </td>",
"       <td>",
"        Asymptomatic to cutaneous, mucocutaneous, or visceral disease",
"       </td>",
"       <td>",
"        Similar to human disease",
"       </td>",
"       <td>",
"        Focal areas of world",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_23_22908=[""].join("\n");
var outline_f22_23_22908=null;
var title_f22_23_22909="Hyponatremia demyelination";
var content_f22_23_22909=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F76471&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F76471&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 503px\">",
"   <div class=\"ttl\">",
"    Course of osmotic demyelination in hyponatremia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 483px; height: 262px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Clinical course in seven previously healthy women show developed postoperative hyponatremia and seizures presumably due to cerebral edema. Rapid correction of the plasma sodium concentration was associated with late deterioration into coma or a permanent vegetative state that may have been due to osmotic demyelination.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Arieff, AI, N Engl J Med 1986; 314:1529.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_23_22909=[""].join("\n");
var outline_f22_23_22909=null;
var title_f22_23_22910="Worry record";
var content_f22_23_22910=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F83340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F83340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Worry record",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 609px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Craske MG, Barlow DH. Mastery of Your Anxiety and Worry, 2nd, Oxford University Press, New York 2006. p.17. By permission from Oxford University Press, Inc. (",
"     <a href=\"file://www.oup.com\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"      www.oup.com",
"     </a>",
"     ).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_23_22910=[""].join("\n");
var outline_f22_23_22910=null;
var title_f22_23_22911="Standing thigh stretch";
var content_f22_23_22911=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75432&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75432&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Flexibility exercise: Thigh (standing)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Here's an exercise that stretches your thigh muscles. If you've had hip or back surgery, talk with your doctor before trying this stretch.",
"    <ol>",
"     <li>",
"      Stand behind a sturdy chair with your feet shoulder-width apart and your knees straight, but not locked.",
"     </li>",
"     <li>",
"      Hold on to the chair for balance with your right hand.",
"     </li>",
"     <li>",
"      Bend your left leg back and grab your foot in your left hand. Keep your knee pointed to the floor. If you can't grab your ankle, loop a resistance band, belt, or towel around your foot and hold both ends.",
"     </li>",
"     <li>",
"      Gently pull your leg until you feel a stretch in your thigh.",
"     </li>",
"     <li>",
"      Hold position for 10 to 30 seconds.",
"     </li>",
"     <li>",
"      Repeat at least three to five times.",
"     </li>",
"     <li>",
"      Repeat at least three to five times with your right leg.",
"     </li>",
"    </ol>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: file://go4life.niapublications.org (Accessed December 2, 2011).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_23_22911=[""].join("\n");
var outline_f22_23_22911=null;
